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The antioxidant enzyme extracellular superoxide dismutase (EC-SOD) is abundant in the lung 
and limits inflammation and tissue injury in response to many pulmonary insults. Previous 
studies reported a loss of full-length EC-SOD from the lung parenchyma with accumulation of 
proteolyzed EC-SOD in the airspace after interstitial lung injury.  However, following airspace-
only inflammation (pneumonia), EC-SOD accumulates in the airspace without a loss from the 
interstitium, suggesting this antioxidant may be released from an extrapulmonary source.  
Because leukocytes are known to express EC-SOD and are prevalent in the bronchoalveolar 
lavage fluid after injury, it was hypothesized that these cells may transport and release EC-SOD 
into airspaces.  To investigate this, bone marrow chimeras were generated using wild-type and 
EC-SOD knockout (KO) mice.  Following intratracheal treatment with asbestos, reconstituted 
mice without pulmonary EC-SOD expression, but with EC-SOD in infiltrating and resident 
leukocytes did not have detectable levels of EC-SOD in the airspaces.  In addition, leukocyte-
derived EC-SOD did not significantly lessen inflammation or early stage fibrosis.   
Although these results indicate that leukocyte-derived EC-SOD is not influential in 
asbestos-induced interstitial lung injury, EC-SOD in these cells may play a role in attenuating 
pneumonias and other inflammatory diseases.  To test this hypothesis, wild-type and EC-SOD 
KO mice were given Escherichia coli pneumonia.  Notably, even though EC-SOD KO mice had 
greater pulmonary inflammation than wild-type mice, there was less bacterial clearance from 
their lungs following infection.  While EC-SOD expression has been previously reported in 
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macrophages and neutrophils, its function and subcellular localization in these inflammatory 
cells is unclear.  In this study, EC-SOD was found to be in membrane bound vesicles of 
phagocytes.  This finding led to the hypothesis that inflammatory cell EC-SOD may play a role 
in antibacterial defense.  To investigate this, phagocytes from wild-type and EC-SOD KO mice 
were evaluated.  While macrophages lacking EC-SOD produced more oxidants than EC-SOD 
expressing cells after stimulation, they had significantly impaired phagocytosis and bacterial 
killing ability.  Overall, these studies suggest that while EC-SOD inside leukocytes does not 
contribute to interstitial lung injuries, it plays a central role in mediating bacterial infections by 
facilitating bacterial clearance and limiting inflammation by promoting phagocytosis. 
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1.0  INTRODUCTION 
1.1 THE LUNG 
The lung is a vital organ that is elegantly structured for its function in respiration and host 
defense.  The major function of the lung is to exchange gases between the bloodstream and the 
air we breathe, oxygenating the blood while excreting carbon dioxide.  In addition to respiratory 
gas exchange, the lung is constantly exposed to and challenged by foreign material as one 
breathes.  Numerous immune and non-immune defense mechanisms exist in the respiratory 
system to efficiently remove these threats without damaging lung tissue.   
1.1.1 Structure and Function of the Lung 
When one breathes, inspired air enters the respiratory tract and travels through the airways, 
which consist of two zones:  the conducting zone and respiratory zone1.  With gradual reduction 
in diameter and multiple branching, the conducting airways begin at the trachea and divide into 
the bronchi, bronchioles, and finally down to the terminal bronchioles.  At this point, the 
respiratory zone of the lower respiratory tract begins with the respiratory bronchioles and ends 
with alveoli, where gas exchange occurs1.  The blood-gas barrier is extremely thin 
(approximately 0.2 µm thick) with a large surface area estimated at 80 to 140 m2 (nearly the area 
of a single tennis court) making it well suited for exchanging gases by simple diffusion2.  
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Specifically, this alveolated region of the lung facilitates the transport of oxygen to hemoglobin 
in the blood while carbon dioxide is released from the blood to the airspace to be exhaled (Figure 
1).  
 
Figure 1: Respiratory Gas Exchange.   
The major function of the lung is to exchange gases between the bloodstream and the air we breathe.  Specifically, 
the alveoli of the lung facilitate the transport of oxygen to hemoglobin in the blood while carbon dioxide is released 
from the blood to the airspace to be exhaled. Figure modified from previous work3. 
 
 
Histologically, the lung parenchyma has a honeycomb-like morphology that is comprised 
of alveoli, pulmonary vessels, and bronchioles.  The alveolar epithelium is comprised of three 
main cell types:  type I epithelial cells, type II epithelial cells, and macrophages2.  Type I cells 
have an extremely thin cytoplasm that stretches over the capillaries that are intertwined in the 
alveoli.  The blood-air barrier is formed by the basal lamina of type I cells and the endothelium.  
Although type I cells comprise less than half of the lung’s cell population, they occupy 90% of 
its surface area2.  Type II cells are cuboidal, surfactant-producing cells that can serve as 
progenitor cells for injured type I cells. Lastly, alveolar macrophages are derived from 
monocytes circulating in the blood and can reside in alveoli for months or years.  These resident 
alveolar macrophages function in immunological defense as they are responsible for sequestering 
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particles and foreign molecules, killing invading microorganisms, and recruiting other leukocytes 
in response to lung damage or infection, which will be further discussed in Section 1.1.2.2. 
1.1.2 Host Defense in the Lung 
Due to its extremely large surface area and the continual inhalation of air and its contents, the 
lung is constantly exposed to foreign particles and pathogens.  Therefore, a plethora of immune 
and non-immune defense mechanisms exist to help remove foreign species from the respiratory 
system.  In the lung, the barrier function and mucociliary clearance provided by the epithelium as 
well as the cellular innate immune response serve as the first line of defense against inhaled 
respiratory pathogens.    
1.1.2.1 Barrier Function of the Epithelium 
In the lung, the epithelium of the airways provides both a mechanical and chemical barrier 
against foreign material and pathogens4.  Structurally, the surfaces of the upper and lower 
airways and of the alveoli are lined with an epithelial layer that rests on a basement membrane.  
The epithelial cells form intercellular tight junctions that provide a protective seal from the 
external environment4, 5.   
For additional protection, the airway epithelium is also involved in mucociliary 
clearance, which is designed to remove unwanted pathogens and foreign material.  Ciliated cells 
and mucus-producing goblet cells of the airway epithelium are primarily involved in this defense 
mechanism.  In the large airways, the submucosal glands, which lie beneath the epithelium and 
connect to the surface by ducts, and goblet cells of surface epithelium are both responsible for 
mucus production5.  In the highly efficient mucociliary clearance system, mucus coats the 
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inhaled pathogen or particle preventing it from adhering to the epithelium and the movement of 
the cilia of the ciliated cells transports the contaminated mucus towards the oropharyngeal 
cavity, where it is removed by swallowing or expelled by coughing5.  Mucus also contains 
antimicrobial peptides and proteins as well as high molecular weight mucin glycoproteins that 
assist in immunologic defense by directly targeting the microorganisms in the lung6. 
In addition to mucus, pulmonary surfactants also play a key role in the innate immune 
system by controlling inflammation and prevent microbial infection of the distal lung7.  Type II 
alveolar epithelial and clara cells of the terminal bronchioles are the source of surfactant protein 
(SP)-A, SP-B, SP-C, and SP-D2.  All pulmonary surfactants are vital for normal alveolar 
function.  Among these surfactant components, SP-A and SP-D are well characterized and are 
known to be important in lung host defense.  Specially, SP-A and SP-D bind and coat the surface 
of pathogens, inflict damage to microbial membranes, and mediate microbial phagocytosis 
(opsonization) as well as alter inflammatory responses by alveolar macrophages8. 
Epithelial cells function as more than just a mere physical barrier; they also have an 
important role in the innate immune response by producing a range of chemical substances to 
assist immune cells in removing the threat.  The epithelium serves as a source of antimicrobial 
peptides and proteins and anti-inflammatory molecules that are important for host defense5.  In 
addition to these effector molecules that directly target the foreign material, epithelial cells can 
also serve as orchestrators of innate immunity by secreting cytokines, chemokines, and growth 
factors, which further activate the innate immune response in the lung9, 10. 
1.1.2.2 Innate Immune Cells and Mediators 
The innate immune system is an inherent, constantly active, and antigen-nonspecific defense 
mechanism that involves an initial cellular response to eliminate microbes and prevent infection.  
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The response of the innate immune system occurs immediately or within hours of exposure to 
the foreign substance4.  Phagocytic cells, such as macrophages and neutrophils, play a key role in 
innate immunity because they recognize, ingest, and destroy invading foreign pathogens and 
particles.  Such pathogens must overcome this defense to establish a pulmonary infection or 
induce pulmonary injury. 
When inhaled pathogens and particles avoid the mucociliary clearance system and reach 
the epithelium of the lower respiratory tract, resident macrophages are present to provide 
additional defense and attempt to remove these substances.  Macrophages are long-lived immune 
cells that are present in both the interstitium and the alveoli.  These cells are continuously 
derived from monocytes produced from the bone marrow that migrate into the tissue and 
mature5.  In most instances, macrophages eliminate threats from the lung without initiating an 
inflammatory response or activating host immune responses.  In fact, up to 1010 particles per day 
reach the alveoli and are cleared unknowingly due to the efficient defense mechanisms of the 
epithelium and resident alveolar macrophages11.  However, if the infection or particulate burden 
overwhelms this defense mechanism, alveolar macrophages and other pulmonary cells, such as 
epithelial cells, secrete cytokines and chemokines to initiate inflammation and to recruit 
neutrophils to the site of injury or infection to assist with the elimination of the microbe. 
Neutrophils are short-lived phagocytes that serve as the second line of defense against the 
pulmonary threat.  Although neutrophils are normally not present in the pulmonary airspaces, 
they are poised near the walls of the lung microvasculature to rapidly migrate into the lung when 
recruited during an infection or injury4.  Therefore, the presence of neutrophils in the lung is 
indicative of inflammation and may promote severe lung injury.  In fact, excessive neutrophil 
accumulation leads to acute lung injury and acute respiratory distress syndrome (ARDS)12, 13.   
  6 
Microbial recognition in innate immunity is mediated by pattern recognition receptors 
(PRRs) expressed by phagocytes and soluble proteins in the blood and extracellular fluids14.  
PRRs are present on the cell surface, in endosomal vesicles, and in the cytoplasm of phagocytes 
and are designed to recognize conserved structures that are characteristic of microbial pathogens, 
but not mammalian cells.  The microbial substances that interact with PRRs are called pathogen-
associated molecular patterns (PAMPs)14.  Different classes of microbes (i.e. gram-positive 
bacteria, gram-negative bacteria, fungi, and viruses) express different PAMPs, such as 
unmethlyated CpG DNA, bacterial lipids and carbohydrates, and viral RNA14.  Although the 
innate immune system has limited diversity when compared to the adaptive immune system, it is 
estimated that the innate immune system can recognize about 103 different PAMPs14.   In 
addition to these cell-associated pattern recognition receptors, there are soluble recognition 
molecules in the blood and extracellular fluids (e.g. collectins in the alveoli) that facilitate 
clearance by enhancing uptake into cells via opsonization or by activated extracellular killing 
mechanisms. 
There are several types of PRRs expressed on the cell surface that recognize PAMPs and 
opsonin-coated microbes.  Some PRRs, such as toll-like receptors (TLRs), promote 
inflammatory responses to enhance killing of microbes; whereas other PRRs, including C-type 
lectins (e.g. mannose receptors), scavenger receptors, and Fc receptors, mainly participate in the 
uptake of microbes14.   In addition to receptors on the plasma membrane, nucleotide-binding 
oligomerization domain-like receptors and caspase activation and recruitment domain-containing 
proteins are cytoplasmic receptors that recognize intracellular pathogens and activate 
inflammatory responses.   
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The direct binding of pathogens, particles, or opsonized microbes to cell surface 
receptors, such as C-type lectins, scavenger receptors, and Fc receptors, leads to phagocytosis 
(Figure 2).  Phagocytosis is a dynamic and energy-dependent process by which neutrophils and 
macrophages engulf large particles (>0.5 µm in diameter)14.  Once a microbe binds the receptors 
on the phagocyte, the plasma membrane in the region of the receptor begins to redistribute, and 
extends a cup-shaped projection around the microbe.  By sequential receptor-ligand interactions, 
this protruding membrane extends beyond the diameter of the pathogen or particle and fuses at 
the apex of the foreign substance to form an intracellular vesicle.  This vesicle, called a 
phagosome, contains the ingested foreign particle or pathogen and breaks away from the plasma 
membrane.  Once inside the cell, phagosomes fuse with lysosomes to generate phagolysosomes 
in which the pathogen or particle is destroyed by proteolytic enzymes, reactive oxygen species 
(ROS), and reactive nitrogen species (RNS).  Notably, ROS can be generated by a multi-
component, membrane associated nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase in a process known as the respiratory burst15.  Briefly, NADPH oxidase reduces 
molecular oxygen (O2) into ROS, such as superoxide (O2•-) radicals, with the reduced from of 
NADPH acting as a cofactor.  In addition to ROS, macrophages produce RNS, mainly nitric 
oxide (NO•) by the action of the cytosolic enzyme, inducible nitric oxide synthase (iNOS).  ROS 
and RNS generation for the purpose of host defense will be further discussed in Section 1.5.4.   
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Figure 2: Phagocytosis and intracellular destruction of microbes.  
The first step in phagocytosis is the recognition of the microbe or particle.  Some cell surface receptors directly bind 
these substances and others recognize and bind opsonized microbes or particles.  The foreign microbe or particle is 
internalized into a phagosome, which then fuses with the lysosome to form the phagolysosome.  Once in the 
phagolysosome, the microbe is killed by reactive oxygen or nitrogen species (ROS and RNS, respectively) and 
proteolytic enzymes.  (iNOS=inducible nitric oxide synthase, O2=molecular oxygen, NO•=nitric oxide) Figure 
modified from previous work14.   
 
Aside from phagocytosis, other PRRs serve to signal microbial presence and mount the 
appropriate immune response.  The most well studied and characterized PRRs are the TLRs that 
are expressed on various immune cells including epithelial cells, leukocytes, and lymphocytes16.  
Phagocytes have both plasma membrane-bound (TLR1, TLR2, TLR4, and TLR5) and endosome 
membrane-bound TLRs (TLR3, TLR7, TLR8, and TLR9) that are able to recognize bacterial 
pathogens in the lung17, 18.  Ligand recognition by the TLRs stimulates a complex signaling 
cascade that leads to the activation of transcription factors (one such being nuclear factor-κB 
  9 
(NF-κB)) and production of pro-inflammatory cytokines and chemokines.  Specifically, 
activation and signaling through these receptors in response to microbial components leads to the 
release of pro-inflammatory cytokines, such as interleukin-1β (IL-1β), IL-6, IL-12, and tumor 
necrosis factor (TNF)-α, as well as the chemokines, such as IL-8, keratinocyte-derived 
chemokines, macrophage inflammatory protein (MIP)-2 from activated immune cells4, 17, 18.   
Successful engulfment and ingestion of a pathogen or particle is necessary to contain the 
antimicrobial arsenal in the phagolysosome.  However, when neutrophils and macrophages are 
strongly activated or are unable to phagocytose the foreign pathogen or particle, these cells can 
release lysosomal enzymes, ROS, and RNS that can injure normal host tissue.  Therefore, while 
the antimicrobial arsenal of phagocytic cells is beneficial in eradicating infections, it also can 
inadvertently damage the lung and lead to serious and lethal complications, such as sepsis and 
ARDS19-21.   
1.2 INTERSTITIAL LUNG DISEASE 
Interstitial lung disease (ILD) is the general term for a group of potentially debilitating 
pulmonary disorders characterized by excessive deposition of collagen in the lungs.  Thickening 
of the alveolar septa significantly decreases lung elasticity and severely impairs normal 
respiration.  ILDs can occur spontaneously (idiopathic pulmonary fibrosis) or in response to 
known stimuli such as environmental, occupational, or chemical exposures (e.g. asbestosis, 
silicosis, bleomycin- or radiation-induced pulmonary fibrosis), secondary to other diseases 
(collagen vascular disease, scleroderma, and rheumatoid arthritis), or a familial syndrome22, 23.  
ILDs have high rates of morbidity and mortality due to both pulmonary and cardiovascular 
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complications.  The pathogenesis of ILDs is not fully understood, but oxidant/antioxidant 
imbalances and inflammation are believed to contribute to these diseases.   
1.2.1 Idiopathic Pulmonary Fibrosis 
Idiopathic pulmonary fibrosis (IPF) is the most common ILD characterized by irreversible and 
progressive fibrosis.  Currently, it is estimated that the prevalence of IPF is 14-42.7 per 100,000 
people with an incidence of 6.8-14 cases per 100,000 in the general population24.  The prognosis 
for IPF is poor and the median survival is 3 to 5 years after diagnosis24, 25.  The prevalence of IPF 
is higher in men than women and is known to increase with age26.   In fact, IPF most commonly 
presents in patients between the ages of 50 and 70.  The median age at the time of diagnosis is 66 
years old24, 26. 
1.2.1.1 Clinical and Pathology Features 
IPF is a progressive, life-threatening ILD of unknown etiology.  Patients usually present with a 
nonproductive cough and shortness of breath, or dyspnea, upon exertion27.  As the disease 
progresses, these symptoms become more severe as the collagen deposition restricts the ability 
for the lung to fully expand.  The majority of IPF patients eventually die from hypoxemia 
resulting from reduced oxygen exchange due to alveolar fibrosis and respiratory failure.  
However, pulmonary hypertension28, 29, acute exacerbations30, 31, and pneumonia32 are also 
causes of ILD-associated death.  Acute exacerbations occur in approximately 10-15% of all IPF 
patients and are characterized by rapid deterioration of lung function, increased hypoxemia, 
acute inflammation, and the absence of an infection, heart failure, and sepsis30, 32. 
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 IPF is diagnosed using information gathered from physical examination, chest 
radiography, pulmonary function tests, high-resolution computed tomography, and lung biopsy.  
The American Thoracic and European Respiratory Societies established specific diagnosis 
criteria for IPF, which includes: 1) surgical biopsy revealing a histologic pattern consistent with 
usual interstitial pneumonia (UIP, described below), 2) exclusion of known causes of ILDs (i.e. 
chemical and environmental exposures), 3) abnormal pulmonary physiology with evidence of 
restriction and impaired gas exchange, and 4) patchy areas of fibrosis in the peripheral, 
subpleural and basilar areas of the lung identified by high-resolution computed tomography and 
chest radiography27. 
IPF is characterized histopathologically by the presence of UIP.  UIP is characterized by 
temporal and spatial heterogeneity meaning the histologic presence of areas of normal lung 
intermixed with immature/active and mature interstitial fibrosis33.  This temporal heterogeneity 
with fibroblastic foci, or areas of active fibrosis characterized by aggregates of spindle-shaped 
myofibroblasts, is the hallmark of UIP.  Moderate inflammation is also present mainly in fibrotic 
areas and is comprised of macrophages, neutrophils, lymphocytes, mast cells, and eosinophils33, 
34.  Upon gross pathological examination, the fibrosis in the lung is most pronounced in the lower 
lobes and in subpleural areas.  As the disease progresses, the normal lung architecture becomes 
increasingly distorted and takes on a honeycomb-like appearance, which is indicative of end-
stage disease33, 34.  Bronchoalveolar lavage fluid (BALF) from the lungs also reveals the presence 
of inflammatory cells similar to what is seen histologically.   
1.2.1.2 Treatments for IPF 
Currently available therapies for IPF are inadequate as they provide little benefit to the patients. 
Established treatment modalities include the use of immunosuppressive/cytotoxic drugs 
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(cyclophosphamide and azathioprine), anti-inflammatory agents (corticosteroids, prednisone), 
anti-fibrotic agents (colchicine and interferon-γ), and antioxidants (N-acetylcysteine)35.  Whether 
used alone or in combination, these drugs have limited to modest therapeutic success for IPF 
patients36-38.  In addition, many treatments are limited by severe adverse side effects39, 40.   
Novel anti-inflammatory (etanercept) and anti-fibrotic (pirfenidone) agents for the 
treatment of IPF are currently under clinical investigation, but have not shown significant 
benefits to patients thus far41.  To date, lung transplantation is the only effective treatment for 
IPF42 and the 5-year survival rate after transplantation is approximately 50-60%43.  With 
ineffective treatment options, the outcome for patients with IPF and other ILDs is dismal.  
Therefore, the need for new therapies to treat this debilitating disease is evident. 
1.2.2 Asbestosis 
Asbestosis is an ILD caused by the inhalation of asbestos fibers typically from environmental or 
occupational exposure.  Asbestosis is further classified as a form of pneumoconiosis, or 
pulmonary disease caused by excessive amounts of dust in the lung44.  In addition to asbestosis, 
asbestos exposure can lead to the development of other fatal non-malignant pulmonary diseases 
(pleural plaques and pleural effusions) as well as lung cancer (mesothelioma and bronchogenic 
carcinoma)45, 46. 
Asbestos-induced lung diseases are a significant health concern as approximately 27 
million workers were exposed to aerosolized asbestos fibers between 1940 and 197947.  
Specifically, miners, millers, and textile, insulation, and shipyard workers have the highest risk 
of asbestos-related diseases due to their heavy occupational asbestos exposure48, 49.  Symptoms 
typically present 20 to 40 years after the initial exposure to asbestos47. 
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1.2.2.1 Asbestos  
Asbestos is a term for naturally occurring silica-containing mineral fibers that have high tensile 
strength and heat and chemical resistance making them ideal for commercial and industrial 
applications49. The types of asbestos are divided into two groups: serpentine and amphiboles.  
Chrysotile asbestos is the sole member of the serpentine group and the fibers are curly and 
flexible50.  In the United States, approximately 95% of the asbestos used commercially was 
chrysotile asbestos48.  Unlike the serpentine group, amphiboles are straight, rigid fibers and 
include crocidolite (blue asbestos), amosite (brown asbestos), tremolite, anthrophyllite, and 
actinolite50.  Amosite and crocidolite asbestos were the primary amphiboles used commercially.  
Generally, amphiboles are considered to be more toxic than chrysotile asbestos as amphibole 
fibers are rigid, more durable, become easily lodged in the lung parenchyma, and are difficult to 
clear from the lung.   
1.2.2.2 Clinical and Pathologic Features 
The clinical, physiological, and pathological findings of asbestosis are similar to that of IPF.  
Clinically, patients present with dyspnea and dry cough and pulmonary function tests reveal 
defects in lung physiology48.  Notably, asbestos exposure leads to irreversible and progressive 
fibrosis analogous to IPF.  Histologic diagnosis of asbestosis requires the presence of diffuse and 
bilateral pulmonary interstitial fibrosis, with the classical UIP pattern (temporal heterogeneity) 
and the presence of asbestos bodies in the lung44.  Under light microscopy, asbestos bodies 
appear as golden brown, segmented, dumbbell-shaped structures covering a fiber51 (Figure 3). 
This iron-containing proteinous coating is thought to result from the inability of alveolar 
macrophages to effectively phagocytosis the fiber (frustrated phagocytosis) and increased 
exocytotic activity52.  This coating makes the asbestos fiber nonfibrogenic and noncytotoxic 
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when compared to an uncoated fiber51, suggesting that this is a compensatory host defense 
mechanism.  
 
Figure 3: Asbestos body. 
Asbestos bodies are asbestos fibers that have become covered with iron, protein, and polysaccharides and have a 
golden brown, dumbbell shaped appearance microscopically.  The process of asbestos body formation is not well 
understood but is thought to involve the action of macrophages.  Accumulations of black anthracitic pigments are 
also visible in this lung section. Image courtesy of Dr. Tim Oury. 
 
Similar to IPF, gross pathological findings reveal that asbestosis presents as a diffuse 
interstitial fibrosis in the lower region of the lungs close to the pleura. Honeycombing is also 
often seen in advance disease48.  However, asbestosis differs from IPF in that the clinical 
manifestations are less severe and the rate of disease progression is generally slower44.  Studies 
have also shown that asbestosis increases the risk of lung cancer and mesothelioma.  The usual 
therapeutic approaches for fibrotic lung diseases (discussed in Section 1.2.1.2) are also 
ineffective for the treatment of asbestosis45.   
1.2.3 Pathogenesis of IPF and Asbestosis 
ILDs, like IPF and asbestosis, are largely considered diseases of abnormal wound repair that 
result in pulmonary fibrosis53.  The underlying mechanisms behind the development of fibrosis 
are thought to involve alveolar re-epithelialization, myofibroblast differentiation/activation, 
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matrix remodeling, oxidative stress, and inflammation54.  Particularly, the role of inflammation 
in disease pathogenesis is controversial as therapeutic strategies to suppress inflammation, such 
as corticosteroids, have not been successful for treating these conditions36-38.  However, 
inflammation is still seen to be important in ILD pathogenesis as inflammatory cells and 
mediators are detected in BALF and lung biopsies of IPF patients and fatal acute exacerbations 
are characterized by an immense inflammatory cell influx55.  Specifically, increased numbers of 
alveolar macrophages, neutrophils, and eosinophils are seen in the BALF of IPF patients56-58 and 
have been associated with worse prognosis59, 60.  In addition to inflammation in the airspaces, 
neutrophil infiltration is observed in the honeycomb-like fibrotic areas of lung biopsies from IPF 
patients and is correlated with decreased survival61.   
Both activated inflammatory cells and alveolar epithelial cells release oxidants, 
proteinases, cytokines, chemokines, and growth factors that can induce both inflammation and 
fibrogenesis in the lung.  Numerous cytokines, chemokines, and growth factors are involved in 
chemotaxis and the activation of immune cells.  More importantly, many pro-inflammatory 
cytokines and mediators are known to be elevated in lung tissue and fluids from IPF patients, 
including but not limited to IL-462, IL-562, IL-1362, MIP-1α63, monocyte chemoattractant protein-
164, IL-864, 65, and macrophage colony-stimulating factor66, 67.  In addition to inflammation, 
inflammatory cells are essential for the production and activation of mediators of fibrogenesis, 
such as transforming growth factor (TGF)-β 68, 69, matrix metalloproteinases, and platelet derived 
growth factor70.  These pro-fibrotic mediators are also found to be increased in the lungs of IPF 
patients68, 70.   Overall, these studies show that inflammation plays a role in the pathogenesis of 
ILDs by inducing tissue damage, contributing to a pro-fibrotic environment, and altering 
remodeling in the lung.   
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While studies have shown asbestosis has many of the same underlying molecular 
mechanism as IPF, asbestos fibers in the lung also directly contribute to the pathogenesis of this 
disease.  As macrophages unsuccessfully attempt to phagocytose the asbestos fibers, this 
frustrated phagocytosis stimulates the release of copious amount of pro-inflammatory signals and 
ROS71, 72 from these cells, which may contribute to the pathogenesis of this disease.    
1.3 PULMONARY INFECTION 
Globally, acute lung infections are the leading infectious cause of premature death with a greater 
disease burden than either cancer or HIV/AIDS, and its incidence is not affected by 
socioeconomic status12.   In the United States, pulmonary infections in the form of pneumonia 
are responsible for one sixth of all deaths73.  Despite advances in antimicrobial therapy, rates of 
pneumonia mortality have not decreased within the past 50 years12, 13, 74.  In addition, the 
emergence of antibiotic-resistant strains and new organisms is constant and complicates the 
efficiency of new and current therapies.  Severe forms of pneumonia can substantially 
compromise normal lung function and can lead to serious respiratory complications such as 
ARDS.   
1.3.1 Causes and Diagnosis 
Pneumonia is broadly defined as any infection located in the lung and affects people of any age.  
However, infection is more serious in patients who are very young, over 65 years of age, have 
underlying medical problems such as heart disease, diabetes, sickle cell disease, and chronic lung 
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disease, or are immunocompromised75.  Pneumonia is commonly spread from person to person 
by contact with infected respiratory secretions.   
Pneumonia is an infection of the gas-exchanging alveoli of the lung that is most 
commonly caused by bacteria, but can also be caused by viruses, fungi, parasites, and other 
infectious agents.  It may present as an acute or chronic disease.  In addition, this alveolar 
infection can manifest in an entire lobe of the lung (lobar pneumonia) or can have a patchy 
distribution that generally involves more than one lobe adjacent to the bronchi 
(bronchopneumonia)76.   
Routine testing for microbial etiology is not usually performed because empiric treatment 
is extremely effective77.  However, microbial diagnosis, often through examination of Gram-
stained sputum and blood cultures, is important for patients with pneumonia acquired in a 
clinical setting as these patients are usually already taking high doses of antibiotics.  However, 
the presence of an infiltrate on plain chest radiograph is considered the standard for diagnosing 
pneumonia when clinical and microbiological features are also present78. 
Pneumonias are classified as typical or atypical depending on their clinical presentation76.  
Patients with typical pneumonia present with a sudden onset of high fever, chills, pleuritic chest 
pain, and a productive mucopurulent cough that are normally due to a bacterial pathogen73.  On 
the other hand, atypical pneumonias often develop as the results of a viral infection and patients 
present with fever without chills and a non-productive cough with scant and watery sputum 
production, which preceded upper respiratory symptoms76.   
Pneumonias can also be classified either by the specific pathogen or by the clinical 
setting in which the infection was occurred.  Even if a specific pathogen cannot be determined, 
pneumonia acquired from each distinct setting has common pathogens that are implicated in 
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disease pathogenesis.  There are a number of pneumonia syndromes, but the most frequently 
seen are community-acquired acute and atypical pneumonias and nosocomial or hospital 
acquired pneumonia73.  Streptococcus pneumoniae is the most common cause of community-
acquired acute pneumonia leading to hospitalization in adults79.  The histopathologic hallmark of 
acute pneumonia is the presence of neutrophils within the alveolar spaces.  Unlike community 
acquired acute pneumonia, community acquired atypical pneumonias usually result from viral, 
Chlamydia pneumoniae, or Mycoplasma pneumoniae infections and histologically mononuclear 
leukocytes accumulate in the thickened alveolar wall instead of the airspaces73.  Nosocomial or 
hospital acquired pneumonia is acquired by patients in a hospital setting and can result from 
mechanical ventilation referred to as ventilator-associated pneumonia76.  Nosocomial infections 
are often caused by more resistant strains of microbes73 (i.e. Escherichia coli, Pseudomonas 
species, and Staphylococcus aureus) as these patients are usually already taking high doses of 
antibiotics.  
While pneumonias are usually treated successfully, severe lung infection can occur and 
lead to serious complications including tissue destruction and necrosis (lung abscess) and 
infection outside of the lung in the pleural space (empyema)76.  Furthermore, primary 
pneumonia, which can be viral, bacterial, or fungal, is the major precursor of serious and lethal 
complications, such as ARDS and sepsis80.  With no effective pharmacological therapy, ARDS is 
a debilitating and severe acute lung injury (ALI) with high morbidity and mortality due to sepsis 
and multiple organ failure81.  In the United States, ALI/ARDS occur in approximately 190,000 
people annually with an estimated mortality rate of around 40%82.  Similar to ILDs, there are no 
effective pharmacological treatments for ALI/ARDS.  However, limiting the severity of 
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pneumonias would likely be beneficial for preventing these complications, as pneumonia is the 
most common cause of ALI/ARDS.   
1.3.2 Treatment 
Patients with community-acquired pneumonias are primarily managed outside of the hospital 
with oral antibiotic treatment; however, elderly patients (over 65 years of age) represent 
approximately 60% of patients hospitalized for this condition83.  Respiratory infections are 
typically treated with antibiotics given orally (for community-acquired pneumonias) or through 
inhalation (ventilator-acquired pneumonia) or intravenous administration (for nosocomial 
pneumonias).  Systemic corticosteroid therapy is also being used, but has demonstrated limited 
success84-86.   
Although treatment for pneumococcal infections with penicillin and other antibiotics in 
most cases is effective, some stains of microbes have become resistant to these drugs.  Therefore, 
prevention of pneumonia by vaccination has become increasingly important for high risk 
individuals, which include those who are less than two years old or more than 65 years old, who 
have long-term preexisting health problems, and who have weakened immune systems.  Other 
risk factors include smoking and a previous diagnosis of asthma.  Currently, a 23-valet 
polysaccharide pneumococcal vaccine (PPV-23) for use in adults and a 13-valet conjugate 
vaccine (PCV-13) for use in infants are available to protect against the most common strains of 
pneumococcal bacteria responsible for severe pneumococcal infections87.  To date, the efficacy 
of the pneumococcal polysaccharide vaccine for preventing pneumococcal infection is 
controversial88-92.  
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1.3.3 Pathogenesis of ALI/ARDS 
Although the pathogenesis of ALI/ARDS is not fully understood, neutrophil-dependent 
endothelial and epithelial injury are thought to contribute to the accumulation of protein-rich 
edema seen in the lungs of ALI/ARDS patients80.  Injury to the endothelium is thought to result 
from excessive neutrophil accumulation and activation in the microvasculature in the lung.  
Activated neutrophils extravasate across the endothelium into the injured tissue and release toxic 
agents, like proteases (matrix metalloproteinases and elastase), defensins, oxidants, and pro-
inflammatory cytokines80, 93.  In addition to activating neutrophils, these pro-inflammatory 
mediators stimulate the endothelium to increase expression of the potent neutrophil 
chemoattractants, IL-8, and leukocyte adhesion molecules on the cell surface93.  These 
inflammatory mediators in turn increase vascular permeability and directly damage the 
endothelium.  In addition to endothelial injury, transepithelial migration of neutrophils into the 
airspaces of the lung is also thought to be involved in the pathogenesis of ALI/ARDS.  Under 
physiological conditions, neutrophils migrate across the epithelium into the airspaces without 
compromising the integrity of the epithelial surface94, 95.  However, activated neutrophils are 
thought to damage the alveolar epithelium by releasing toxic proteases, ROS, and RNS that 
induce the dissolution of tight junctions and alveolar epithelium cell death96.   
1.4  MURINE MODELS OF PULMONARY DISEASE 
Studying the pathogenesis of pulmonary diseases in humans is difficult and confounded by the 
fact that patients already have advanced disease when they present with symptoms and receive 
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medical care.  Therefore, researchers use in vivo animal models to study ILDs and respiratory 
infections to elucidate and better understand the mechanisms underlying these conditions.  There 
are advantages and disadvantages to each animal model and no one model accurately 
recapitulates human lung disease pathogenesis.  However, animal models are essential to study 
the evolution of these conditions and have led to the discovery of many key components and 
mediators of disease pathogenesis in animals that are likely also involved in human disease. 
Specifically, the models of asbestos-induced interstitial lung injury and bacterial pneumonia in 
mice will be discussed further as these models were used to investigate the role of cellular 
extracellular superoxide dismutase (EC-SOD) in pulmonary inflammation.   
1.4.1 Asbestos-induced Interstitial Lung Injury 
Numerous animal models of ILD exist, such as bleomycin, asbestos, silica, irradiation, 
fluorescein isothiocyanate, transgenic models with pulmonary specific transgenes, and virus 
targeted transgene delivery97.  Bleomycin and asbestos are the most commonly used agents and 
have been shown to cause acute inflammation followed by abnormal repair and fibrosis in the 
lung.  Although there are numerous methods of administration, intratracheal instillation of these 
agents is an efficient method as it allows for exact dosing, uniform distribution through the 
lungs, and rapid inflammatory response and development of fibrosis as early as 7 days post-
exposure.   
Although bleomycin is the most prevalent model used, the fibrosis that develops 
following bleomycin treatment is self-limiting with a homogenous distribution in the lung.  
Notably, asbestos instillation in animals leads to irreversible and progressive fibrosis with 
temporal heterogeneity, which is histologically similar to IPF (described in Section 1.2.1.1).  
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Although controversial, the asbestos-induced interstitial lung injury method likely serves as the 
best model for studying the mechanisms underlying the pathogenesis of asbestosis and IPF.  
Another advantage to using the asbestos model is that the fibers can be seen in the BALF as well 
as in fibrotic areas in the lung providing objective evidence that the intratracheal instillation was 
successful.   
The murine model of asbestosis produces a progressive peribronchial and alveolar septal 
fibrosis98, 99.  In mice, crocidolite asbestos induces an acute inflammatory response that develops 
within 24 hours and remains during the first seven days following exposure98.  Both interstitial 
and airspace inflammation are present.  Typically, the inflammation is predominantly 
neutrophils, but macrophages are also present and are thought to play an important role in 
disease progression98, 100, 101.  The development of fibrosis following crocidolite asbestos 
exposure is observed as early as seven days and continues to progress, never resolving.   
1.4.2 Experimental Models of Bacterial Pneumonia 
Human pneumonia is modeled with experimental infections in animals, most frequently mice. 
Bacterial inoculation in the lungs causes inflammation that leads to the accumulation of a large 
number of neutrophils in the airspaces, but does not lead to significant amounts of interstitial 
inflammation or fibrosis102, 103. 
Several methods exist to produce experimental pneumonia in mice, each with its own 
considerations.  Common methods include, but are not limited to inhalation of aerosolized 
microorganisms, intranasal instillation, and intratracheal inoculation104. In particular, 
intratracheal instillation of a microbial suspension allows for direct inoculation of the lower 
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respiratory tract and is advantageous as it permits precise dosing to the lungs to each individual 
animal. 
1.5 OXIDATIVE STRESS 
Living organisms are constantly exposed to ROS and RNS as a consequence of normal metabolic 
processes or abnormal reactions and disease.  Specifically, these reactive species can cause 
chemical modifications in lipids, proteins, DNA, and transcription factors that can seriously 
impair the biological functions of these molecules.  To compensate for the presence of ROS and 
RNS, endogenous antioxidant defenses are necessary to remove these reactive species and 
prevent oxidative damage to the surrounding tissues.  Oxidative stress results from a disruption 
of this balance either from increased production of ROS and/or RNS or decreased levels of 
antioxidants and other scavenging enzymes, and may lead to tissue damage and cellular 
dysfunction.  The lung is especially vulnerable to oxidative damage due to its high oxygen 
tension and large epithelial surface area that is constantly bombarded by particulates (discussed 
in Section 1.1).  Therefore, various antioxidants are present to scavenge these reactive species 
and maintain low levels of oxidants in the lung.  
1.5.1 Reactive Oxygen Species 
Oxygen is necessary for the biological processes within all aerobic organisms.  Under normal 
conditions, molecular oxygen is a diradical as it has two unpaired electrons105, 106.  The majority 
of cellular oxygen is consumed by the mitochondria, where it acts as a terminal electron acceptor 
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and undergoes a tetravalent reduction to water in a reaction catalyzed by cytochrome oxidase in 
the mitochondrial electron transport chain107.  Oxygen can also be reduced via a non-enzymatic 
pathway through four sequential one-electron reductions107. 
When oxygen (O2) undergoes four sequential one-electron reductions, a number of ROS 
are formed before conversion to water.  These ROS include but are not limited to superoxide 
(O2•-, Reaction 1), hydrogen peroxide (H2O2, Reaction 2), and hydroxyl radical (•OH, Reaction 
3). Although molecular oxygen is not very reactive itself, these metabolites of oxygen rapidly 
participate in other chemical reactions that can initiate cell and tissue damage.  Of these 
metabolites of oxygen, O2•- and •OH are free radical species as they contain one unpaired 
electron, whereas H2O2 is not.   
The O2•- radical anion is always produced as a result of a one-electron reduction of 
molecular oxygen (Reaction 1).  However, O2•- can also be formed from the accidental leakage 
of electrons from the mitochondrial respiration chain and through enzymatic reactions (xanthine 
oxidase and NADPH oxidase). Specifically, activated macrophages and neutrophils, among 
many other cells, can produce O2•- using NADPH oxidase107 that is necessary for host defense.  
O2•- is not able to diffuse freely across plasma membranes due to its charge, but can utilize anion 
channels to move in and out of cells108.  In addition, O2•- can undergo further reduction to form 
additional ROS. 
O2  + e- → O2•-     (1) 
O2•- + e- + 2H+ → H2O2    (2) 
H2O2 + e- → OH- + •OH    (3) 
•OH + e- + H+ → H2O     (4) 
  25 
Although O2•- is a free radical, it is relatively stable and may act either as a reductant 
(electron donor) or as an oxidant (electron acceptor).  Indeed, O2•- is seen to act as both an 
oxidizing and reducing agent in the spontaneous or enzymatically-calatyzed dismutation reaction 
by the antioxidant enzymes, superoxide dismutases (SODs)108 (Reaction 5).  In this dismutation 
reaction, half of the O2•- is oxidized to O2, while the other half is reduced to H2O2.   
In addition to H2O2, O2•- is also a precursor for •OH.   O2•- can produce •OH through the 
direct reduction of H2O2 (Reaction 8).  This reaction, known historically as the Haber-Weiss 
reaction, is thermodynamically unfavorable in biological systems without the presence of metal 
ions109.  In the iron-catalyzed Haber-Weiss reaction, O2•- acts as a reductant by reducing ferric 
iron (Fe3+) to ferrous iron (Fe2+) (Reaction 6) followed by the Fenton reaction in which Fe2+ 
catalyzes the transformation of H2O2 into the most reactive radical species, •OH (Reaction 7)109.   
Although other transition metal ions are capable of catalyzing this reaction, the iron-
catalyzed Haber-Weiss reaction is thought to be one major mechanism by which the highly 
reactive •OH is produced biologically108, 110.  Free metals available to undergo 
oxidation/reduction and catalyze this reaction are rare as they normally found bound to carrier 
proteins and inaccessible for redox reactions.  Therefore, this reaction is limited by the 
availability and location of metal ions in the body.  However, this reaction can readily occur in 
response to the presence of exogenous metal ions.  Notably, asbestos fibers are a source of free 
O2•- + Fe3+ → Fe2+ + O2     (6) 
Fe2+ + H2O2 → Fe3+ + •OH + OH-    (7) 
Net Reaction:  H2O2 + O2•- → O2 + •OH +OH-  (8) 
O2•- + O2•- + 2H+ → H2O2 + O2   (5) 
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iron that could catalyze ROS production111 thereby contributing to the development of interstitial 
lung injury.  One study noted that ROS generated by the iron in chrysotile and crocidolite 
asbestos, can activate the cytokine TGF-β1, while addition of antioxidants (e.g. SODs) abrogated 
this effect 112. 
•OH has a very short half-life and has the highest oxidation potential of all aerobic 
metabolites105.  •OH is too reactive to traverse cell or organelle membranes106 and therefore acts 
locally and will react with any biomolecules.  In addition to the reaction of H2O2 with metal ions, 
the formation of •OH can also occur by the breakdown of peroxynitrite (ONOO-, Section 1.5.2).   
1.5.2 Reactive Nitrogen Species 
Similar to oxidative stress, nitrosative stress occurs in disease states in which excess RNS leads 
to the modification of biological molecules.  NO• is a free radical capable of forming other 
powerful oxidants that modify and alter the function of proteins.  NO• is produced by nitric oxide 
synthases (NOSs) from L-arginine and oxygen113.  Of the three isoforms, neuronal NOS and 
endothelial NOS produce low levels of NO•.  The third isoform, iNOS can produce high levels of 
NO•, up to 20 times more than the other NOS enzymes114.   iNOS was first identified and has 
been extensively studied in macrophages.  iNOS is normally absent, but can be induced by 
bacterial lipopolysaccharide (LPS) and cytokines (TNF-α, IL-1β, and interferon-γ) to produce 
high levels of NO•114, 115.  Indeed, production of NO• is an essential part of the nonspecific 
immune defense system116.  NO• can easily diffuse in and out of cells.  One electron reduction 
reactions of NO• will form other nitrogen species: nitrite (NO2-), nitrogen dioxide (NO2•), and 
finally nitrate (NO3-)115. 
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The free radical NO• can react with other species with unpaired electrons to form other 
powerful oxidants.  NO• can react very rapidly with O2•- (1.9 x 1010 M-1s-1) to produce 
peroxynitrite (ONOO-, Reaction 9)106 that can oxidize thiols and modify tyrosine residues on 
proteins.  Notably, the reaction between O2•- and NO• occurs more rapidly than the SOD-
catalyzed dismutation of O2•-.  Although stable at an alkaline pH, ONOO- is easily protonated 
(pKa = 6.8117) to form peroxynitrous acid (ONOOH, Reaction 10) and then rapidly decomposes 
to form •OH and NO2• in physiological or acidic conditions (Reaction 11).  
1.5.3 Antioxidant Defenses in the Lung 
The lungs are at risk for oxidant-mediated damage as they have an enormous epithelial surface 
area that is in direct contact with ambient air.  Inhaled air may contain numerous oxidants, gases, 
particulates, toxicants and pollutants that can lead to tissue injury.  Therefore, the lung has a 
multitude of antioxidant systems available to maintain normal pulmonary cellular function and 
control redox homeostasis.  The high reactivity and toxicity of ROS and RNS are 
counterbalanced by both enzymatic and non-enzymatic endogenous antioxidant defenses.  
Various antioxidant enzymes exist in the lung to scavenge different ROS.  One family of 
antioxidant enzymes that rapidly scavenge O2•- are the SODs.  There are three different SOD 
isozymes that exist in eukaryotes.  First, copper/zinc-containing SOD (CuZn-SOD or SOD1) is 
present in almost all eukoaryotic cells in the cytosol and nucleus.  Manganese-containing SOD 
O2•- + NO• → ONOO-    (9) 
ONOO- + H+ → ONOOH    (10) 
ONOOH → •OH + NO2•    (11) 
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(Mn-SOD or SOD2) is present in the mitochondria.  Lastly, extracellular SOD (EC-SOD or 
SOD3) is found in the extracellular matrix (ECM) and fluids.  Specifically, EC-SOD is highly 
expressed in the lung118 and will be discussed in more detail in Section 1.6. 
Glutathione peroxidase and catalase are antioxidant enzymes that both scavenge H2O2 in 
the lung.  Specifically, glutathione peroxidases are selenium-containing enzymes that utilize 
reduced glutathione (GSH) as an electron donor to reduce H2O2 to water106.  Glutathione 
disulfide (GSSG) is formed in the course of this reaction and is reduced back to GSH by 
glutathione reductase.   The ratio of GSH to GSSG is often used as an indicator of oxidative 
stress.  Healthy, nonstressed cells are known to have a high intracellular GSH:GSSG ratio107, 119.  
In particular, alveolar macrophages are known to have high levels of GSH when compared to 
type II epithelial cells and Clara cells120.  In addition to glutathione, most aerobic organisms have 
catalase located in peroxisomes to enzymatically catalyze the removal of H2O2 to water and 
oxygen106, 107, 121.  Catalase is a tetrameric hemoprotein that is also found in the cytoplasm, 
mitochondria, and BALF122, 123.  While glutathione peroxidase, coupled with reduced GSH, 
readily removes H2O2 at low concentrations, catalase is most effective in the presence of higher 
concentrations of H2O2107.    
In the lung, non-enzymatic antioxidants also exist to help prevent oxidative tissue 
damage.  Vitamins, such as α-tocopherol (vitamin E), ascorbate (vitamin C), and β-carotene 
(vitamin A) and other small molecules and proteins (albumin, taurine, and uric acid) have 
antioxidant functions119, 124.  Storage and transport proteins for transition metals, such as 
transferrin (iron), also have antioxidant capacity as they bind metal ions making them 
unavailable to participate in chemical reactions, thus preventing the formation of •OH via Fenton 
type chemistry121(as demonstrated in Reactions 6 and 7 above).   
 29 
1.5.4 Oxidants and Host Defense 
An integral part of host defense in the lung is the activation of phagocytes resulting from 
recognition and ingestion of the inhaled microbes and the production of the potent arsenal (large 
amounts of ROS) needed for efficient microbial killing.  Activated phagocytes (macrophages, 
neutrophils, and eosinophils) are able to produce large amount of O2•- as they possess NADPH 
oxidase, an enzyme that catalyzes that production of O2•- from oxygen and NADPH (Reaction 
12).  Once the foreign microbe is internalized, phagocyte NADPH oxidase, assembled on the 
phagolysosomal membrane, reduces molecular oxygen into ROS, such as O2•-.  This process, 
known as the oxidative burst, plays an essential role in host defense, but these reactive species 
can also damage the surrounding tissue and alter cell functioning if released from the cell125.  In 
fact, overproduction of lysosomal enzymes, ROS, and RNS during bacterial infections have led 
to serious lung-associated pathophysiological consequences, such as ARDS19-21.  In addition, the 
importance of the production of O2•- via the NAPDH oxidase in host defense is clearly evident as 
patients with chronic granulomatous disease (CGD), an inherited disorder of NAPDH oxidase, 
suffer from chronic bacterial and fungal infections and excessive inflammatory responses.     
In addition to oxidative species, neutrophils also release myeloperoxidase (MPO) that 
aids in microbial killing.  Specifically, MPO uses H2O2 (produced from the dismutation of O2•-) 
to produce the bactericidal oxidant hypochlorous acid or bleach (Reaction 13).  Aside from host 
H2O2 + Cl- → H2O + OCl-    (13) 
NADPH + 2O2 → NADP+ + 2O2•- + H+  (12) 
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defense, the release of MPO can also be detrimental to the host tissue as MPO is known to use 
H2O2 and NO2• to generate reactive nitrogen species126.   
 
1.5.5 Oxidative Stress in ILD 
Oxidant/antioxidant imbalances have been implicated in the pathogenesis of ILD127-130.  Studies 
have shown that the BALF of IPF patients have decreased reduced glutathione levels129 and 
increased markers of oxidative stress, such as lipid peroxidation129 and 8-isoprostane131.  In the 
lungs of IPF patients, oxidative stress is also observed as increased levels of nitrotyrosine, a 
ONOO--mediated protein modification, are detected in the lung tissue132.  The antioxidant EC-
SOD is also seen to be significantly decreased in the fibrotic areas of the lungs of patients 
diagnosed with UIP133.   
Similar to what has been observed in human pulmonary disease, oxidant/antioxidant 
imbalances are also important in the pathogenesis of animal models of ILD.  It is well-known 
that injurious agents like bleomycin134 and asbestos99, utilized in animal models of ILD, induce 
the formation of ROS.  Many studies have shown that asbestos exposure in vitro and in vivo 
leads to ROS formation that is detectable through markers of oxidative stress71, 135, 136.  In the 
lung, exposure to asbestos can also lead to increased enzymatic production of NO• by iNOS in 
macrophages137-139 and lung epithelial cells140.  The administration of an antioxidant SOD 
mimetic was shown to attenuate pulmonary fibrosis141 while overexpression of EC-SOD was 
able to protect mice from radiation-induced142 and bleomycin-induced interstitial lung injury143.  
Furthermore, studies have demonstrated that EC-SOD knockout (KO) mice have enhanced 
inflammation as well as increased lung damage and fibrosis when compared to wild-type mice 
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following bleomycin- and asbestos-induced pulmonary injury99, 144.  Taken together, all of these 
studies suggest that oxidants play an important role in the development of interstitial pulmonary 
disease and that antioxidant enzymes, such as EC-SOD, may attenuate this damage. 
1.5.6 Oxidative Stress in Pulmonary Infection 
Oxidant/antioxidant imbalance has been reported in various respiratory diseases including 
pneumonia.  During pneumonia, there is a massive influx of activated phagocytes into the lower 
airways to kill invading microorganisms using ROS, RNS, and lysosomal enzymes.  This 
respiratory burst is an essential part of the defense system but may also result in oxidative stress.  
Indeed, increased markers of oxidative stress, such as lipid peroxidation and ROS production, 
and decreased levels of antioxidants have been found in the BALF and the blood of patients with 
pneumonia145-147.  Furthermore, high concentrations of H2O2 were found in breath condensate of 
patients with ARDS or acute respiratory failure due to severe pneumonia148. 
Animal models of pulmonary infection have also noted oxidant/antioxidant imbalances in 
the lungs.  For instance, Hennet and coworkers found that influenza virus-induced pneumonia in 
mice caused a decrease in total glutathione and in vitamin C and E149.  Several other studies 
using animal models of infection noted that inhibition of oxygen radicals through administration 
of antioxidants or increased lung SOD levels significantly reduced lung injury and improved 
survival rate of infected animals150-153.  Overall, these studies suggest oxidative stress may play a 
significant role in the pathogenesis of pulmonary infections. 
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1.6 EXTRACELLULAR SUPEROXIDE DISMUTASE 
Endogenous antioxidant enzymes are normal cellular defenses that can protect against ROS-
induced tissue injury. One family of antioxidant enzymes is the SODs that catalyze the 
conversion of O2•- radicals to H2O2 and molecular oxygen.  There are three isozymes in this 
family that have been identified in mammals.  
1.6.1 Historical Background 
In 1969, Irwin Fridovich and Joe McCord discovered the first SOD enzyme in mammalian 
tissue, which was named copper/zinc SOD (CuZn-SOD) due to its metal content154.  This 
enzyme with SOD activity was previously known as copper-containing human erythrocuprein.  
CuZn-SOD exists as a 32 kDa homodimer and is present in the cytoplasm and nucleus of every 
cell type examined, where it acts as a bulk scavenger of O2•-155.  A few years later in 1973, a 
second SOD enzyme, manganese SOD (Mn-SOD) was discovered in mitochondria of eukaryotes 
by Richard Weisinger and Irwin Fridovich156.  Mn-SOD is a 96 kDa homotetramer and is located 
primarily in the mitochondrial matrix156. CuZn-SOD and Mn-SOD are not structurally similar 
and their biological activities can be distinguished based on cyanide sensitivity; the activity of 
Mn-SOD is unaffected, while CuZn-SOD is inhibited by cyanide118. 
A little over ten years after the original discovery of SOD, Stefan L. Marklund and his 
colleagues observed that CuZn-SOD only accounted for a small amount of the cyanide-sensitive 
SOD activity in human plasma157.  Their further investigations revealed that a higher molecular 
weight protein that was distinctly different from CuZn-SOD with cyanide-sensitive activity was 
present in human extracellular fluids158.  These observations led to the discovery of a third 
  33 
mammalian SOD isoenzyme in 1982118.  Marklund and coworkers termed this enzyme 
extracellular SOD (EC-SOD) as it was first detected in human extracellular fluids such as 
plasma, lymph, ascites, and cerebrospinal fluid158.  In addition, EC-SOD was originally purified 
from human lung and was characterized as a homotetramer with three variants based on its 
affinity for heparin glycosaminoglycan118.  These great discoveries have lead to over 40 years of 
research on SODs and their ability to prevent oxidant-induced tissue damage and disease. 
1.6.2 Structure of EC-SOD 
EC-SOD (EC 1.15.1.1) is a 135 kDa homotetrameric copper and zinc-containing glycoprotein 
that is comprised of two disulfide linked dimers118, 159 (Figure 4).  This intrasubunit disulfide 
bridge involved cysteines located in the carboxyterminal end of each subunit160, 161.  The 
complete tetramer is formed by noncovalent interactions between N-terminal domains of all four 
subunits162, 163.  Each subunit of EC-SOD contains one copper and one zinc atom118, 164, which 
are required for its enzymatic activity, and a positively charged matrix-binding domain at the C-
terminal region that localizes it to the ECM.  The matrix-binding domains can be post-
translationally cleaved without affecting enzymatic activity165.   
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Figure 4: Schematic illustration of EC-SOD. 
Each subunit of human EC-SOD (A) and mouse EC-SOD (B) is synthesized with a matrix-binding domain (bolded 
and underlined) at the C-terminus.  Two identical subunits are linked via a disulfide bond formed between cysteines 
in the C-terminal region.  EC-SOD functions as a homotetramer that is held together by noncovalent interactions at 
the N-terminal domains.  (C) EC-SOD has different matrix affinity depending on the proteolysis of the positive 
charged matrix-binding domains.  Type C EC-SOD, in which all found subunits contain a matrix-binding domain, 
has high matrix affinity and is predominantly found in the lung parenchyma.  Proteolysis results in either partial 
(Type B) or complete (Type A) reduction of EC-SOD affinity and clearance of the protein from the tissue into the 
serum.  Figure adapted from previous works159, 160. 
 
In humans, EC-SOD is a secretory protein as it is synthesized with an 18 amino acid 
signal peptide preceding the 222 amino acids of the mature enzyme (Figure 4A)166.  Although the 
first 95 amino acids of the protein have no homology to either of the other SODs, amino acids 
96-193, which contain the active site of the enzyme, show strong homology with eukaryotic 
CuZn-SOD167.  Finally, amino acids 194-222 in the carboxyl-terminal domain of EC-SOD is 
strongly hydrophilic as it contains six positively charged amino acids with the sequence Arg-
Lys-Lys-Arg-Arg-Arg166.  This domain was originally termed the heparin-binding domain due to 
its strong affinity to heparin118, 168, 169.  However, full-length EC-SOD is now known to bind to 
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other ECM components, like type I collagen170 and hyaluronan171, and therefore is more 
accurately referred to as the matrix-binding domain.  EC-SOD is known to exist in three forms, 
which are characterized by matrix affinity118, 168: Type A (low affinity), Type B (moderate 
affinity) and Type C (strong affinity) (Figure 4C).  Additionally, there is only one possible N-
glycosylation site on EC-SOD (Asn-89 of human EC-SOD, Figure 4A and Asn-97 in mouse EC-
SOD, Figure 4B) located in the N-terminus of the protein, which confers its affinity to 
concanavalin A160.  Notably, both mouse and human EC-SOD share this overall structure (Figure 
4). 
The main function of EC-SOD is to scavenge O2•- and thereby lower levels of harmful 
oxidants in the body.  EC-SOD catalyzes the dismutation of two O2•- anions to H2O2 and oxygen 
at a rate constant of 1 x 109 M-1 s-1 118.  EC-SOD is a very stable glycoprotein and can withstand 
high temperature, pH extremes, and high urea and guanidinium chloride concentrations172.  
However, like CuZn-SOD, the activity of EC-SOD can be inhibited by cyanide, azide, H2O2, 
diethyldithiocarbamate, and sodium dodecyl sulfate173. 
Located on chromosome 4 (human) and chromosome 5 (murine), the EC-SOD gene is 
approximately 5900 base pairs long and comprised of three exons and two introns 174, 175.  The 
third exon contains the entire coding region for EC-SOD.  The human EC-SOD gene is 
approximately 60% homologous to human CuZn-SOD with minimal homology to human 
MnSOD167, 176.  The promoter region of the gene contains antioxidant response elements, 
activator protein-1 binding sites, xenobiotic response elements, and NF-κB motif175. 
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1.6.3 Location and Function of EC-SOD 
As its name implies, EC-SOD is located in extracellular fluid and in the ECM of tissues169, 177-179.  
Specifically, tissue EC-SOD is thought to account for 90-99% of the EC-SOD in the body177, 178 
and is mostly homoteterameric high matrix affinity type C protein variant169, 180.  Although the 
tissue distribution of EC-SOD differs among species, generally the lung and kidney have the 
highest EC-SOD content177, 181. EC-SOD is abundant in lung tissue of humans and mice and is 
produced by type II epithelial cells, bronchial epithelial cells, macrophages, and neutrophils179, 
182, 183.  EC-SOD is also present in high concentrations in the arteries and plasma, where all three 
variants of EC-SOD are known to be present181, 184.  
The matrix-binding domain of EC-SOD plays an essential role in regulating tissue 
distribution and the proteolysis of this domain changes the location and function of EC-SOD in 
the body.  Numerous proteinases have been shown to be able to cleave the matrix-binding 
domain of EC-SOD; however, the proteinases responsible for the cleavage of this domain in vivo 
are unknown. Indeed, full-length EC-SOD has a tissue half-life of approximately eighty five 
hours while partially (Type B) and completely proteolyzed EC-SOD (Type A) only have a half-
life of twenty and seven hours, respectively180.   
Additionally, a single nucleotide polymorphism in SOD3 gene (R213G) located in the 
coding region for the carboxyl-terminal domain is been shown to markedly decrease EC-SOD’s 
binding affinity to the matrix185.  Indeed, heterozygote carriers of this polymorphism have 
approximately 10-fold higher plasma concentrations of EC-SOD than non-carriers186.  Patients 
with this R213G polymorphism are known to have increased risk of ischemic heart disease 
which is thought to results from the loss of EC-SOD from the arterial walls187.  But, these 
patients also are protected against chronic obstructive pulmonary disease188. 
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1.6.4 EC-SOD in Pulmonary Disease 
Numerous studies have shown that the localization of EC-SOD to the lung parenchyma is 
essential for protecting it from ROS-mediated injury.  Notably, EC-SOD is known to protect the 
lung against pulmonary injury from bleomycin143, 144, 189, asbestos98, 99, radiation142, 190, 
hyperoxia191-193, hemorrhage194, 195, endotoxin196, 197, and bacteria103.  One mechanism by which 
EC-SOD is known to exert its protective effect in the lung is by directly binding to and 
preventing the oxidative fragmentation of type I collagen144, 170, hyaluronan171, and heparan 
sulfate proteoglycans198, 199. Therefore, loss of EC-SOD from the matrix to the airspace may 
result in increased oxidative fragmentation of matrix components and results in amplification of 
inflammation and fibrosis.  The importance of endogenous pulmonary EC-SOD was also 
recently highlighted in a study by Gongora and colleagues, which showed that an acute loss of 
EC-SOD resulted in 85% mortality secondary to the spontaneous development of ARDS200.  This 
indicates that EC-SOD is essential for protecting the lungs against inflammation and injury even 
in ambient air.   
Prior studies have demonstrated that proteolysis of the heparin-binding domain of EC-
SOD occurs in a number of ILD models including bleomycin189, asbestos99, and hyperoxia193.  
Following interstitial lung injury, the depletion of EC-SOD from the lung parenchyma and 
accumulation of its proteolyzed form (lacking its heparin-binding domains) in the BALF is 
observed 99, 189.  While this suggested that EC-SOD is being cleaved from the lung parenchyma 
and released into the alveolar lining fluid, further studies using an airspace-only model of 
inflammation (pneumonia) provided evidence that challenged this hypothesis103. 
In response to bacterial pneumonia, the accumulation of EC-SOD in the airspaces and the 
retention of EC-SOD in the lung parenchyma is observed.  Numerous studies have also reported 
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the presence of EC-SOD in inflammatory cells of the lung99, 143, 182.  Based on these findings, it 
was hypothesized that inflammatory cells may transport and release EC-SOD into airspaces 
following inflammation resulting from interstitial lung injury or bacterial inoculation.  In 
addition, this leukocyte-derived EC-SOD would help limit inflammation and subsequent lung 
injury or infection.  As these hypotheses were investigated, new insight into the functional role 
of EC-SOD inside leukocytes was uncovered.   
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2.0   LEUKOCYTE-DERIVED EXTRACELLULAR SUPEROXIDE DISMUTASE IN 
INTERSTITIAL PULMONARY INJURY 
2.1 RATIONALE AND HYPOTHESIS 
EC-SOD is the only extracellular SOD and is highly expressed in the lung compared to other 
tissues.  Many studies have shown EC-SOD limits the development of fibrosis in experimental 
models and plays an important role in regulating inflammatory responses following pulmonary 
insult.  Proteolysis of the matrix-binding domain of EC-SOD has also been noted in these ILD 
models and results in the depletion of EC-SOD from the lung parenchyma and accumulation of 
proteolyzed EC-SOD in the BALF99, 189.  One mechanism by which EC-SOD is known to exert 
its protective effect in the lung is by directly binding to and preventing the oxidative 
fragmentation of type I collagen144, 170, hyaluronan171, and heparan sulfate proteoglycans198, 199. 
Therefore, loss of EC-SOD from the matrix to the airspace may result in increased oxidative 
fragmentation of matrix components and result in amplification of inflammation and fibrosis.  
While the above studies suggest that EC-SOD is being cleaved from the lung parenchyma 
and released into the alveolar lining fluid, another study reported an accumulation of proteolyzed 
EC-SOD in the airspaces without a loss of EC-SOD from the lung parenchyma using an 
airspace-only model of inflammation (bacterial pneumonia)103.  In addition, using EC-SOD 
transgenic mice that expressed both mouse and human EC-SOD in the lung, but only mouse EC-
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SOD in inflammatory cells, only mouse EC-SOD was detected in the BALF103.  These results 
suggested that inflammatory cells, which are known to contain EC-SOD103, 143, 182, could 
transport and release this potent antioxidant into the airspaces after pulmonary injury.  However, 
the contribution of EC-SOD from inflammatory cells in response to interstitial lung injury is still 
unknown.   
Bone marrow chimeric (BMC) mice were generated to directly test the hypothesis that 
leukocytes contribute to EC-SOD accumulation in the alveolar lining fluid following asbestos-
induced lung injury and to examine the impact of leukocyte-derived EC-SOD on inflammation 
and early stage fibrosis in response to asbestos injury. 
2.2 MATERIALS AND METHODS 
2.2.1 Generation of Bone Marrow Chimeric Mice 
2.2.1.1 Animals 
Seven-week-old male C57BL/6 (Taconic, Germantown, NY), C57BL/6 (B6.PL-Thy1a/CyJ, The 
Jackson Laboratory, Bar Harbor, Maine), and EC-SOD null mice (congenic with C57BL/6 
background and bred in our animal facility) were used as donors with seven-week-old male 
C57BL/6 (B6.PL-Thy1a/CyJ, The Jackson Laboratory) wild-type mice and EC-SOD null mice 
as recipients.  The EC-SOD null mice were originally derived by Dr. Stefan Marklund and were 
produced on the C57BL/6 background through the targeted disruption of the mouse ec-sod gene 
with a gene encoding neomycin resistance191.  These mice are currently bred in our animal 
facility at the University of Pittsburgh.  All animals were housed in pathogen free conditions in 
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microisolator cages and all animal experiments were reviewed and approved by the University of 
Pittsburgh Institutional Animal Care and Use Committee.   
Donor mice were euthanized and bone marrow was extracted from the long bones of the 
hind legs.  Recipient mice received 1000 R dose of whole-body irradiation and then were 
injected i.v. via tail vein with 100 µL of 1x Hank’s Buffered Salt Solution (pH 7.1) containing 5 
x 106 bone marrow cells.  Recipient mice received 0.032 mg/ml of Baytril® (Enrofloxacin, 
Bayer Healthcare LLC, Shawnee Mission, Kansas) in their drinking water starting two days 
before and continuing until seven days after irradiation and transplantation. 
2.2.1.2 Verification of Chimerism 
Engraftment of donor cells was determined by flow cytometry using a BD FACS Vantage with 
DiVa and CellQuest analytical software (Becton Dickinson, Franklin Lakes, NJ).  Peripheral 
blood was collected from the lateral saphenous vein in EDTA-coated anticoagulant tubes 
(Brinkmann Instruments, Westbury, New York) from of all BMC mice 33-35 days after 
transplantation201.  All procedures were done in FACS Buffer (1x phosphate buffered saline with 
1% bovine serum albumin).  To verify chimerism, while blood cells were stained with the 
following antibodies for specific cell surface antigens: Fluorescein isothiocyanate-conjugated 
mouse anti-mouse CD 90.1 (Thy-1.1), Phycoerythrin-Cy5-conjugated rat anti-mouse CD8a, 
Phycoerythrin-conjugated rat anti-mouse CD 90.2 (Thy-1.2), and Allophycocyanin-conjugated 
rat anti-mouse CD4.  Cells were then fixed in 2% paraformaldehyde for analyses the following 
day.  BMC mice were allowed to recover for 15 days following this blood collection before 
intratracheal clodronate treatment. 
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2.2.2 Preparation and administration of liposomal clodronate.   
Liposomal encapulation of dichloromethylene diphosphonate (clodronate) was performed as 
previously described202.  In brief, 8 mg of cholesterol and 86 mg of dioleoyl-phosphatidylcholine 
(Avanti, Alabaster, AL) were mixed and dissolved in chloroform.  The chloroform was then 
evaporated under nitrogen and further removed from the liposome preparation using a low 
vacuum speedvac.  The clodronate solution was then prepared by dissolving 1.2 g 
dichloromethylene diphosphonic acid (Sigma-Aldrich Corp., St. Louis, MO) in 5 mL of sterile 
phosphate-buffered saline (PBS) and was added to the liposome preparation.  The resulting 
solution was mixed, sonicated, and then ultracentrifuged at 10,000 g for 1 hour at 4°C.  The 
resulting pellet of liposomes was then resuspended in PBS and ultracentrifuged again using the 
same conditions.  The liposomes were removed, resuspended in PBS resulting in a final 
concentration of liposomal clodronate of 5 mg/mL.  75 µL of liposomal clodronate solution was 
administered by intratracheal instillation to the BMC mice. 
2.2.3 Intratracheal Instillation of Asbestos   
Four weeks following clodronate administration, BMC mice were anesthetized 20%v/v 
isoflurane in propylene glycol (Baxter Healthcare Corp., Deerfield, IL) using the open-drop 
exposure method203 and then intratracheally instilled with 0.14 mg of crocidolite asbestos in 70 
µl of 0.9% sterile saline.  Crocidolite asbestos fibers were greater than 10 μm in length and a 
generous gift from Dr. Andrew Ghio at the Environmental Protection Agency, Research Triangle 
Park, NC.  BMC mice were euthanized 150 mg/kg nembutol intraperitoneally at three and seven 
days post-treatment to assess inflammation and the beginning of the development of fibrosis.   
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BALF was also collected using the following procedure.  Briefly, the trachea was 
surgically exposed and suture was placed underneath the trachea.  Then, a small horizontal 
surface cut was made in the trachea and a 24-gauge lavage needle was placed into the trachea 
and secured with the suture.  BALF was obtained via intratracheal instillation and recovery of 
0.8 ml of 0.9% saline.  The lungs were then inflation fixed with 10% buffered formalin (Fisher 
Scientific, Pittsburgh, PA) for at least 2 hours before incubation in 70% ethanol overnight.  
Lungs were paraffin embedded by Research Histology Services at the University of Pittsburgh.   
2.2.4 Bronchoalveolar Lavage Fluid Analyses 
To determine the number of white blood cells present in the BALF, triplicate counts of BALF 
samples were made using a Z1 Coulter Counter (Beckman Coulter, Fullerton, CA).  To obtain a 
differential count, BALF samples were adhered to glass slides and stained using DiffQuik. The 
number of macrophages, neutrophils, lymphocytes and eosinophils were counted using a light 
microscope (200 cells/slide).  The remaining BALF was centrifuged to remove the cellular 
content and stored at -80°C for later use.  
2.2.5 Detection of Leukocyte-derived EC-SOD   
Total protein in the BALF was determined using Commassie Plus Protein Assay Reagent 
(Pierce, Rockford, IL).  Equal concentrations of BALF protein (8 µg/sample) were boiled in a 50 
mM dithiothreitol and 1% sodium dodecyl sulfate solution for 10 minute, subjected to SDS-
polyacrylamide gel electrophoresis, and then blotted onto polyvinylidene fluoride membranes 
(PVDF, Millipore, Billerica, MA) at 500 mA for 50 minutes.  As a loading control, the PVDF 
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membranes were then stained with Ponceau Red Stain (0.2% Ponceau S, 3% trichloroacetic acid) 
for 15 minutes and quickly destained (40% methanol, 7.5% glacial acetic acid in water) to 
visually verify equal loading of protein in all samples.  The membranes were then blocked 
overnight in 5% milk in 1x phosphate buffered saline with 0.3% Tween-20 (PBST).  Full-length 
and proteolyzed EC-SOD in the BALF was detected using a rabbit anti-mouse EC-SOD 
polyclonal antibody198 (AnaSpec Corporation, San Jose, CA) at a 1:5,000 dilution in 1xPBST.  
After washing the membrane, the secondary antibody donkey anti-rabbit IgG conjugated to 
horseradish peroxidase was added to the blots at a concentration of 1:5,000 in PBST.  ECL Plus 
Western Blotting Detection reagents (GE Healthcare, Piscataway, New Jersey) were utilized to 
visualize bands using the Kodak Gel Logic 2200 Imaging System. 
2.2.6 Histological Analyses 
Hematoxylin and eosin stained lung sections (5 µm thick) were obtained from Research 
Histology Services at the University of Pittsburgh and were scored by a pathologist (Tim D. 
Oury) who was blinded to the sample groups.  Every field in the entire lung section was observed 
with a light microscope (x200 magnification) and scored if at least 50% of the field was alveolar 
tissue.  Scoring was based on the percentage of alveolar tissue with interstitial fibrosis according 
to the following scale:  0= no fibrosis, 1= up to 25%, 2= 25-50%, 3= 50-75%, and 4= 75-100%.  
The pathological index score was then reported as a ratio of the sum of all the scores divided by 
the total number of fields counted for each sample.  
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2.2.7 Statistical Analyses   
All comparisons between three or more groups were made using a one-way ANOVA with 
Tukey’s post-test using GraphPad Prism 5 (GraphPad Software, San Diego, CA).  All values 
shown are mean ± SEM.  A p-value of less than 0.05 was considered statistically significant.   
2.3 RESULTS 
To determine if leukocyte-derived EC-SOD is the source of the EC-SOD that accumulates in the 
alveolar lining fluid in response to interstitial lung injury and to investigate its role in this injury, 
BMC mice were generated as shown in the schematic below (Figure 5).  Wild-type C57BL/6 
Thy-1.1 mice were irradiated and transplanted with bone marrow from EC-SOD KO mice 
(WT/KO) to create BMC mice that lack expression of EC-SOD in circulating leukocytes with 
normal expression of EC-SOD in the lung parenchyma.  Conversely, EC-SOD KO mice were 
irradiated and received bone marrow from wild-type C57BL/6 Thy-1.1 mice (KO/WT) to 
generate mice with EC-SOD expression in leukocytes and no EC-SOD expression in the lung.  
Wild-type C57BL/6 Thy-1.1 mice were irradiated and received bone marrow from wild-type 
C57BL/6 Thy-1.2 mice (WT/WT) and EC-SOD KO mice were irradiated before receiving EC-
SOD KO bone marrow (KO/KO) to serve as transplant controls.  
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Figure 5: Generation of Bone Marrow Chimeric Mice. 
Bone marrow chimeric mice were generated by the irradiation of wild-type and EC-SOD KO recipients and 
subsequent transplantation with wild-type and EC-SOD KO bone marrow from donor mice.  From this process 
shown above, unique chimeras were created to definitively determine the role of leukocyte derived EC-SOD in 
asbestos-induced lung injury. WT/KO mice have EC-SOD expression in their lungs and not in their circulating 
leukocytes, while KO/WT mice that have no pulmonary EC-SOD expression, but EC-SOD inside their circulating 
cells.  WT/WT and KO/KO were generated as controls. 
 
Chimerism of the resulting BMC mice was confirmed by flow cytometry.  Specifically, 
the presence of donor cells in recipient mice after transplantation was evaluated by assessing the 
percentage of total circulating T lymphocytes (Thy 1) from the blood that expressed either Thy 
1.1 or Thy 1.2 alloantigen (Table 1). Values shown are the mean percentage of donor cells in 
total T lymphocytes ± standard deviation (n=8-12 per chimeric group).   
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Table 1. Verification of Chimerism. 
 
It is known that bone marrow transplantation alone is inadequate to repopulate the 
alveolar macrophages in the lung202. As alveolar macrophages are also known to express EC-
SOD103, 143, 182, these cells could also contribute to the EC-SOD that accumulates in the airspace.  
Therefore, in order to reconstitute the resident alveolar macrophages with donor cells, BMC 
mice were intratracheally treated with liposomal clodronate as previously described202.  Using 
this approach, approximately 90% of the lung alveolar macrophages will be repopulated as 
previously reported202.  All BMC mice were then intratracheally treated with asbestos and 
sacrificed either three or seven days post-treatment, as these time points were previously shown 
to coincide with maximal inflammation and the beginning of the development of fibrosis 
respectively 99.  A summary of the experimental design is illustrated below (Figure 6). 
 
 
Figure 6: Summary of the Experimental Manipulations of Bone Marrow Chimeric Mice. 
After irradiation and bone marrow transplantation, bone marrow chimeric mice undergo several procedures and 
treatments: verification of chimerism to ensure efficient reconstitution of donor bone marrow in the recipient mice, 
intratracheal instillation of liposomal clodronate to deplete resident alveolar macrophages and replace them with 
donor-derived cells, and finally intratracheal treatment with asbestos to induce interstitial lung injury. 
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2.3.1 Infiltrating inflammatory cells and resident macrophages are not the source of 
airspace EC-SOD 
To determine whether leukocytes release EC-SOD into the airspaces following asbestos-
induced interstitial lung injury, western blotting was performed on BALF from BMC mice at 
three and seven days after instillation of asbestos.  From this analysis, an accumulation of EC-
SOD was detected in the airspaces of WT/KO mice at both three and seven days post-asbestos 
exposure even though the leukocytes in these BMC mice did not express EC-SOD (Figure 7).  
Furthermore, there was a lack of EC-SOD observed in the BALF of KO/WT mice following 
asbestos injury (Figure 7).  Together, these data demonstrate that leukocytes do not release 
detectable levels of EC-SOD into the airspace three or seven days following asbestos injury.   
 
Figure 7: Absence of airspace EC-SOD in KO/WT mice at both three and seven days post-asbestos exposure. 
Western blotting for EC-SOD was performed on equal protein amounts of BALF (8 µg) from bone marrow chimeric 
mice three and seven days following intratracheal treatment with asbestos.  The absence of EC-SOD in the KO/WT 
BALF indicates that leukocyte-derived EC-SOD does not contribute to the EC-SOD that accumulates in the airspace 
after asbestos-induced lung injury.  EC-SOD positive control (+) was 8 µg of wild-type lung homogenate. 
 
2.3.2 Leukocyte-derived EC-SOD did not affect inflammation after asbestos exposure 
Although significant amounts of EC-SOD from leukocytes could not be detected in the BALF 
after asbestos-induced pulmonary injury, it is still possible that these cells may be releasing EC-
SOD that lessens the magnitude of pulmonary injury in the lung.  To assess the amount of 
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inflammation, the total cells in BALF of the BMC mice were counted at both three and seven 
days following asbestos instillation.  These measurements revealed that leukocyte-derived EC-
SOD had no effect on inflammation resulting from asbestos treatment at either time point (Figure 
8).  Cell differential counting of BALF cells revealed that there were significantly more 
macrophages in the BALF of the KO/WT mice when compared to WT/KO mice seven days after 
asbestos exposure, but the biological significance of this observation is unclear.  Other than this, 
there were no notable differences in the cellular composition of the BALF after injury (Figure 8).   
 
Figure 8: Leukocyte-derived EC-SOD does not alter leukocyte accumulation in response to asbestos. 
Total white blood cells and cell differentials in the BALF of the bone marrow chimeras were measured three (A) and 
seven days (B) after asbestos treatment.  Total cells were calculated by multiplying the cell concentration (cells/mL) 
by the total volume of BALF recovered.  Data were analyzed using a one-way ANOVA with Tukey’s post-test and 
are means (± SEM). *p<0.05 when WT/KO and KO/WT macrophages are compared, n=5-6 mice/group for three 
day time point and n=3-5 mice/group for seven day time point 
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2.3.3 Leukocyte-derived EC-SOD does not lessen the early fibrotic response to asbestos 
 Since EC-SOD is also known to be an anti-fibrotic agent, analyses were conducted to determine 
if leukocyte-derived EC-SOD could limit the early fibrosis seven days after asbestos treatment.  
To test this hypothesis, hematoxylin and eosin-stained lung sections were scored by a pathologist 
who was blinded to sample groups and experimental treatment. Individual fields were examined 
with a light microscope at ×200 magnification and scoring in each field was based on the 
percentage of alveolar tissue with interstitial fibrosis.  Histological analyses of the lungs revealed 
that there were fibrotic areas present in the lungs of all mice (Figure 9A); however, there was not 
a significant difference between any of the BMC mice (Figure 9B).    
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Figure 9: Leukocyte-derived EC-SOD does not alter early fibrosis in response to asbestos. 
Bone marrow chimeras were euthanized seven days after intratracheal treatment with asbestos.  Hematoxylin and 
eosin staining of lung sections revealed that leukocyte-derived EC-SOD did not attenuate asbestos-induced fibrosis 
as fibrosis in the lungs was similar for all mice (A). Representative images shown are at 10x magnification.  
Average histology score also showed no differences in fibrosis and was determined by a pathologist (T.D.O.) 
blinded to groups (B). Data shown are means (±SEM), n=3-5 mice/group 
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2.4 DISCUSSION 
Prior to the current study, it was thought that the EC-SOD accumulating in the airspace 
following an interstitial lung injury was due to a combination of EC-SOD release from the 
interstitium as well as direct release of EC-SOD from the infiltrating inflammatory cells103. Bone 
marrow chimeras were generated to determine the source of airspace EC-SOD during 
inflammation following interstitial lung injury.  The data in Figure 7 clearly shows that the EC-
SOD, which accumulates in the airspace after pulmonary injury, originates solely from the lung 
parenchyma as infiltrating inflammatory cells and resident alveolar macrophages do not 
contribute detectable levels of EC-SOD.   
Furthermore, leukocyte-derived EC-SOD did not appear to protect against asbestos-
induced lung injury as it was incapable of lessening inflammation or early stage fibrosis in vivo. 
Previous work has shown that EC-SOD KO mice have more inflammation than wild-type mice 
twenty-four hours and twenty-eight days following asbestos treatment, while no significant 
difference was noted fourteen days after exposure98.  Therefore, the current observations add to 
and are consistent with this previous data.  Even though EC-SOD is known to be a potent 
antioxidant and anti-inflammatory agent, the EC-SOD produced by leukocytes is not abundant 
enough to lessen the inflammatory response induced by asbestos.  
Prior studies noted that there was significantly more fibrosis in the lungs of EC-SOD KO 
mice when compared to wild-type mice as early as fourteen days following asbestos exposure98.  
Seven days after asbestos instillation is known to be the beginning of the fibrotic phase in this 
injury model. This early fibrotic time point may explain why there is not a significant difference 
in fibrosis between WT/WT and KO/KO mice, but only a trend toward the KO/KO mice having 
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more fibrosis than WT/WT mice.  Overall, these results suggest that leukocyte-derived EC-SOD 
has no effect on the early fibrotic response to asbestos exposure.  
Although the present findings strongly show that the lung parenchyma EC-SOD is being 
cleaved and release into the BALF following asbestos exposure, the possibility does exist that 
leukocytes do release EC-SOD at very low levels that are unable to be detected by western 
blotting.  In addition, as the levels of EC-SOD in the BALF were only measured three and seven 
days following asbestos exposure, it is possible that the inflammatory cells do release EC-SOD 
that is quickly degraded or cleared into the circulation.  Regardless, the overall significance of 
this leukocyte-derived release of EC-SOD in this model of ILD (if it does in fact occur) is trivial 
as leukocyte-derived EC-SOD does not alter inflammation or early stage fibrosis.   
Although leukocytes are not the source of airspace EC-SOD in this lung injury model, 
previous work suggests that inflammatory cells may release EC-SOD into the airspaces after 
pulmonary bacterial infection103.  In addition, EC-SOD KO mice have greater inflammation in 
their BALF when compared to wild-type mice following infection103. Therefore, it is still 
possible that the leukocyte-derived EC-SOD may be released into the BALF and may be 
effective at limiting inflammation following pulmonary infection.   
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3.0  EXTRACELLULAR SUPEROXIDE DISMUTASE IN BACTERIAL 
PNEUMONIA 
3.1 RATIONALE AND HYPOTHESIS 
Acute infection of the lower respiratory tract is the leading infectious cause of premature death 
with a greater disease burden than cancer12, 13, 104.  In the lung, alveolar macrophages and 
neutrophils are phagocytic inflammatory cells that play a central role in the elimination of 
bacterial infections.  As the first line of defense, macrophages and neutrophils produce potent 
molecules, such as ROS and proteases, in an attempt to eliminate microbes.  While this 
antimicrobial arsenal is beneficial for eradicating the infectious organisms, these toxic agents can 
directly cause pulmonary damage and contribute to complications such as ARDS19-21. 
Endogenous antioxidant enzymes are normal cellular defenses that can protect against 
ROS-induced tissue injury.  EC-SOD is a 135 kDa antioxidant enzyme that scavenges the free 
radical O2•-159.  This isozyme of the SOD family is highly expressed in the lung and arteries and 
is bound to the ECM via its positively charged heparin/matrix-binding domain159-161, 181.   In 
addition to its localization on matrices and in extracellular fluids, EC-SOD is also present 
intracellularly in neutrophils and macrophages103, 144, 182.  However, the localization and the role 
of EC-SOD in these inflammatory cells have not been investigated.   
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Few studies have investigated the role of this potent antioxidant in bacterial infections; 
therefore, the present study investigates the response of wild-type and EC-SOD KO mice to live 
Escherichia coli inoculation.  To better understand the role of EC-SOD in infection, the 
subcellular localization and functional role of EC-SOD in inflammatory cells was also 
investigated.  These findings are significant in that EC-SOD located in membrane bound vesicles 
in the cytoplasm of phagocytic cells is shown to be functionally important for innate host defense 
against gram-negative bacterial infections.  
3.2 MATERIALS AND METHODS 
3.2.1 Pneumonia Studies 
Nine week old and sex-matched C57BL/6 mice (Taconic) and EC-SOD KO mice (congenic in 
the C57BL/6 background191) were used for all animal studies.  Animal studies were approved by 
the University of Pittsburgh Institutional Animal Care and Use Committee.  Mice were 
intratracheally instilled with ~1x106 CFUs live E. coli (ATCC 25922) in 50 μL of phosphate 
buffered saline204 and euthanized immediately (0 hours), 6, or 24 hours after inoculation with 
150 mg/mL pentobarbital.  The thoracic cavity was opened by midline incision and the left lung 
was tied off using suture. The entire left lung was removed and placed in 1 ml sterile water for 
subsequent homogenization.  BALF was collected via instillation and recovery of 0.6 ml of 0.9% 
saline from the right lung and the right lung was then inflation-fixed with 10% formalin for 
histological analyses.   
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3.2.2 Sample Processing 
Cell counts and differentials in the BALF and cell differentials were performed as described 
previously (Section 2.2.4).  BALF supernatants were stored at -70 °C until analyses.  The left 
lung homogenates were separated into aliquots for quantitative bacterial cultures, western blot 
analysis, and MPO assays.  In brief, for western blot analyses, buffer was added to an aliquot of 
lung homogenate so that the final concentration of buffer contained 0.5% Triton-X-100, 150 nM 
NaCl, 15 mM Tris, 1 mM Ca Cl2, and 1 mM MgCl2 (pH 7.4), incubated on ice for 30 minutes, 
and spun at 10,000 x g for 20 minutes.  The supernatants were stored at -80ºC to use later. For 
MPO activity measurements, the lung homogenate was added to a buffer so that the final 
concentration of the solution was 50 mM potassium phosphate (pH 6.0), 5 mM EDTA, and 5% 
wt/vol hexadecyltrimethyl ammonium bromide.  This mixture was then sonicated and spun down 
at 12,000 x g for 30 minutes.  The supernatant was then stored at -80ºC until use.   
3.2.3 Bacterial Recovery 
Quantitative cultures of bacterial burden were performed by culturing serial 10-fold dilutions of 
lung homogenates in Luria-Bertani (LB) agar using the pour plate method to determine the 
number of colony-forming units. 
3.2.4 Myeloperoxidase Activity Assay 
Lung homogenates in 50 mM potassium phosphate (pH 6.0), 5 mM EDTA, and 5% wt/vol 
hexadecyltrimethyl ammonium bromide were assayed in triplicate at a 1:30 ratio (vol/vol) in 
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assay buffer (50 mM potassium phosphate buffer pH 6.0, 0.167 mg/ml o-dianisidine 
dihydrochloride, 0.0005% hydrogen peroxide, 0.01% hexadecyltrimethylammonium bromide) in 
a 96 well plate. Immediately after addition of assay buffer, MPO activity was monitored by 
measuring the absorbance at 460 nm over 2 minutes.  Relative MPO activity was calculated as 
the change in absorbance over time per left lung (dA/min/left lung). 
3.2.5 Isolation of Macrophages 
Bone marrow-derived macrophages were isolated and cultured from wild-type mice and EC-
SOD KO mice as previously described205, 206.  Briefly, mice were euthanized and femurs were 
dissected from the animal and placed in ice cold 1x Hank’s Buffered Saline pH 7.1 containing 
1% penicillin/streptomycin and 1% fetal bovine serum.  Bone marrow cells were then flushed 
from the bones with 1x Hank’s Buffered Saline pH 7.1 with 1% fetal bovine serum using a 25-
gauge needle until the bone had a translucent appearance. The cells were then filtered through a 
40 µm cell strainer (BD, Franklin Lakes, NJ) and washed twice through centrifugation. Cells 
were plated on 24-well tissue culture grade plates at 1 x 106 cells/well (LPS stimulation) or on 
100 cm VWR Petri dishes at around 4 x 106 cells/dish for all other assays and cultured for seven 
days in 10% L929 conditioned media.  The next day, additional conditioned media was added to 
the culture and the media was then change every two days.  Twenty-four hours prior to use, 
macrophages were washed and cultured with media lacking both antibiotics and L929 
supplement.  Peritoneal macrophages were isolated from the peritoneum via instillation and 
recovery of sterile phosphate buffered saline without calcium or magnesium.  Alveolar 
macrophages were harvested via instillation and recovery of 0.8 ml of cold sterile PBS from the 
lungs.  Both cell types were allowed to adhere at 37°C in a humidified 5% CO2 atmosphere for 2 
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hours.  Non-adherent cells were then removed by gentle washing and remaining cells were 
cultured overnight in media lacking both antibiotics and L929 supplement for experiments.  The 
purity of the cell populations was verified by flow cytometry using macrophage marker PE-
conjugated anti-mouse F4/80 (Molecular Probes, Eugene, OR). For detection of EC-SOD, cell 
lysates were collected in ice-cold lysis buffer with protease inhibitors (1% Triton, 25 mM 
HEPES, 150 mM NaCl, 5 mM EDTA, pH 7.5 with 100 µM 3,4-dichloroisocoumarin, 10 µM E-
64 and 1 mM 1,10-phenanthroline).   
3.2.6 Immuno-labeling 
EC-SOD in human phagocytes in normal lung was localized using electron microscopy with 
immuno-gold labeling as previously described179.  Dr. Tim Oury conducted this work in 
collaboration with Dr. James Crapo and Dr. Ling-Yi Chang while at Duke University.   
3.2.7 Western blot Analyses 
Western blot analysis for EC-SOD in BALF, cell lysate, or lung homogenates was done as 
previously described (Section 2.2.5).  However, equal volume of sample was loaded for the 
western blots of BALF (26 µl/sample) and cell lysate (65 µl/sample).  Equal protein loading was 
used for the lung homogenates (10 µg/sample). After probing for EC-SOD, the blots of cell 
lysate and lung homogenate were stripped and reprobed with antibody against β-actin at a 1:5000 
dilution in 1xPBST as a loading control.  Densitometry was performed by quantifying the band 
intensity and in some cases standardizing to β-actin using Kodak MI Software 4.5.1 SE.   
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3.2.8 EC-SOD Activity Assay 
The activity of EC-SOD in the macrophages was determined using the Nitro Blue Tetrazolium 
Zymography assay as previously described160.  Cell lysates of primary alveolar, peritoneal, and 
bone marrow-derived macrophages (90µl/sample) were collected and 21.2 µg CuZn-SOD 
(bovine liver, Alexis Biochemicals, San Diego, CA) and 2 µg of human EC-SOD were prepared 
as positive controls.  Following non-denaturing PAGE, the gel was soaked, in the dark, in water 
containing 10.5 mg of Nitro Blue Tetrazolium, 1.2 mg of riboflavin and 220 µl of N,N,N’,N’-
tetramethylethylenediamine (100 ml final volume) for 40 min. The gel was then transferred to 
water and developed over a fluorescent light.  Image of the gel was captured using the Kodak 
Gel Logic 2200.   
3.2.9 Oxidant Production by Phagocytes 
Electron paramagnetic resonance (EPR) spectroscopy was performed to determine the location 
and amount of oxidant production in wild-type and EC-SOD KO macrophages 10 minutes after 
stimulation with 15 μg/ml phorbol 12-myristate 13-acetate (PMA).  Peritoneal macrophages 
isolated from wild-type and EC-SOD KO mice were resuspended (1 x 106 cells/ml) in Krebs 
HEPES buffer pH 7.4.  Identification of ROS production (O2•-, ONOO-, and other downstream 
single electron reactive oxygen intermediates) was accomplished by exposing the stimulated 
cells to either 50 μM cell permeable (1-hydroxy-3-methoxy-carbonyl-2,2,5,5-
tetramethylpyrrolidine (CMH)) or 50 μM cell impermeable (1 hydroxy-4-phosphono-oxy-
2,2,6,6-tetramethylpiperidine (PPH)) spin probes (Noxygen Science Transfer and Diagnostics, 
Elzach, Germany) and analyzed using a Bruker eScan Table-Top EPR spectrometer207-209.  
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Various μM amounts of CM radical were measured to generate a standard curve to quantify the 
amount of oxidants produced by wild-type and EC-SOD KO cells.  EPR settings were as 
follows:  field sweep, 50 Gauss; microwave frequency, 9.78 GHz; microwave power 20 mW, 
modulation amplitude, 2 Gauss; conversion time, 327 ms; time constant, 655 ms; receiver gain, 
1x105. All buffers were treated with Chelex resin and contain 25 μM deferoxamine.  Absence of 
transition metals was confirmed by the inability to detect the ascorbyl radical upon exposure of 
buffer to 100 μM ascorbic acid.   
3.2.10 Pro-inflammatory Cytokine Measurements 
Bone marrow-derived macrophages from wild-type and EC-SOD KO mice plated in 24-well 
plates were stimulated with 1 μg/ml LPS from E. coli (O26:B6, Sigma Aldrich).  Cell culture 
supernatants were collected at various time points after stimulation from triplicate wells and 
stored at -80°C for further analysis.  TNF-α was quantified in the supernatants using an Enzyme 
linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions (R&D 
Systems, Abingdon, UK).  The ELISA plates were read using a SpectraMax M2 plate reader, and 
the data was analyzed using SoftMax Pro software (Molecular Devices). 
3.2.11 Culturing of Bacteria for In vitro Studies 
Enhanced green fluorescent protein (EGFP)-expressing E. coli (BL21 strain)210, 211 was grown 
overnight in LB broth with 50 μg/ml ampicillin at 37°C with continuous shaking.  Cultures were 
refreshed and grown for 2 hours to reach log phase, washed with DPBS without calcium and 
magnesium, and used for phagocytosis and bacterial killing studies.   
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3.2.12 Bacteria Killing Assay 
Bone marrow-derived macrophages from wild-type and EC-SOD KO mice (500,000 cells/tube) 
were incubated with EGFP-expressing E. coli at 37ºC (1:100 ratio of cells to bacteria).  Wild-
type and EC-SOD KO cells as well as bacteria alone were incubated as controls.  After one hour, 
the bacteria remaining were cultured in LB agar using the pour plate method to determine the 
number of colony-forming units.  The percentage of bacteria killed was calculated as the average 
CFUs of the bacteria alone minus the CFUs remaining after one hour incubation with cells 
divided by the average CFUs of the bacteria alone multiplied by 100.   
3.2.13 Live Cell Microscopy of Phagocytosis 
Bone marrow-derived macrophages (1 x 105 cells/dish) were plated onto 35mm collagen-coated 
glass bottom dishes (MatTek Corp, Ashland, MA). Multimode imaging (dimensions: X, Y, Z, 
time and color) was used to image cellular interactions between phagocytes and EGFP-
expressing E. coli in a temperature-controlled chamber (Tokai-Hit, Tokyo, Japan) at 37°C. 
Movies were obtained using a Nikon Ti inverted microscope (40x magnification) running NIS-
Elements AR 3.1 software (Melville, NY). Images were collected sequentially with a 
Photometrics CoolSNAP HQ2 camera (Tucson, AZ) using shuttered illumination in both 
fluorescence and differential interference contrast. Movies were analyzed using NIS-Elements 
software.  Phagocytosis was quantified over 1 hour by an observer blinded to the experimental 
groups.   
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3.2.14 Endocytosis Analyses 
Bone marrow-derived macrophages (250,000 cells/tube) were incubated with 5 µg/ml Alexa 
Fluor® 555 dextran (Molecular Probes, Eugene, OR) for 1 hour at either 4°C or 37°C.  Cells 
were then fixed and flow cytometric analysis was done using a BD FACS Vantage with DiVa 
and CellQuest analytical software (Becton Dickinson, Franklin Lakes, NJ).  
3.2.15 Cell Viability Assay 
To determine if there were differences in cell viability between macrophages from wild-type or 
EC-SOD KO mice, bone marrow-derived macrophages were treated with various concentrations 
of PMA (Sigma), LPS (E. coli O26:B6, Sigma), and EGFP-expressing E. coli.  Cell viability was 
measured using CellTiter 96 AQueous Non-radioactive Assay according to manufacturer’s 
instructions (Promega, Madison, WI) or by visual assessment using trypan blue.   
3.2.16 Statistical Analyses 
Data were analyzed using GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA).  Animal 
experiments were analyzed by two-way analysis of variance with a Bonferroni post-test.  
Comparisons with one variable were analyzed using an unpaired t-test.  The number of cells that 
phagocytosed bacteria were compared using a Fisher’s exact test.  All values are means (±SEM) 
unless otherwise noted.  A P value less than 0.05 was considered to be statistically significant. 
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3.3 RESULTS 
3.3.1 EC-SOD limits inflammation following Escherichia coli inoculation 
EC-SOD has been shown to attenuate inflammation and oxidative injury in numerous pulmonary 
disease models; however, few studies have investigated its role in limiting injury in response to 
bacterial infections.  To determine the role of EC-SOD in E. coli pneumonia, wild-type C57BL/6 
and EC-SOD KO mice (congenic with the C57BL/6 strain) received an intratracheal instillation 
of E. coli and were killed immediately (0 hours) or at 6 or 24 hours after inoculation.  The 
expression of EC-SOD in the airspace and lung parenchyma was evaluated in wild-type mice by 
western blot analyses of the BALF and lung homogenates.  Consistent with previous work103, 
bacterial pneumonia leads to a significant increase of EC-SOD in the alveolar lining fluid (Figure 
10), but no loss from the lung parenchyma (Figure 11). 
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Figure 10: EC-SOD accumulates in the BALF after E. coli inoculation. 
EC-SOD levels in the BALF (26 µl/sample) 6 and 24 hours after intratracheal instillation with E. coli were 
measured by western blotting (A).  Densitometry showed increased EC-SOD at both 6 and 24 hours after exposure 
when compared to 0 hours. By 24 hours after inoculation, the majority of EC-SOD found in the BALF was 
proteolyzed EC-SOD.  *p<0.05, one-way ANOVA 
 
To evaluate the importance of EC-SOD in response to bacterial infection, pulmonary 
inflammation was assessed in the BALF and lung tissue of infected wild-type and EC-SOD KO 
mice.  There was no significant difference in inflammation between wild-type and EC-SOD KO 
animals 6 hours after E. coli inoculation based on the cellular content of the BALF and the level 
of MPO and inflammation in the lung (Figure 12).  
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Figure 11: EC-SOD is not depleted from the lung after E. coli inoculation. 
Western blotting was performed on equivalent protein amounts of left lung homogenates (10 µg) from mice exposed 
to E. coli via intratracheal instillation for 0, 6, or 24 hours.  EC-SOD was found to be unchanged at both 6 and 24 
hours after inoculation.  Data shown is from the inoculated wild-type animals.  As expected, no EC-SOD was 
detected in the BALF of the EC-SOD KO animals. 
 
 
Figure 12: EC-SOD knockout and wild-type mice have similar inflammation 6 hours after infection. 
There were a similar number of total cells in the bronchoalveolar lavage fluid (BALF) of EC-SOD knockout (KO) 
mice when compared to wild-type (WT) mice 6 hours after infection (A).  Myeloperoxidase (MPO) activity in lung 
homogenates also showed that EC-SOD KO mice had similar neutrophilic inflammation when compared to WT 
mice after E. coli inoculation (B). Protein in the BALF was measured to assess lung injury and EC-SOD KO mice 
had comparable protein levels in the alveolar lining fluid than WT mice after infection (C).  Data are means (±SEM) 
analyzed by two-way ANOVA with a Bonferroni post-test.  (n=9-11/strain for each timepoint) 
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However, histological examination of the lungs 24 hours after inoculation with E. coli 
revealed an increased number of inflammatory cells in the EC-SOD KO mice when compared to 
the wild-type mice (Figure 13A).  EC-SOD KO mice also had more inflammatory cells in the 
BALF than wild-type mice 24 hours after infection (Figure 13B).  The majority of cells in the 
lung and BALF were neutrophils, although macrophages were also present.  Indeed, there were 
significantly greater numbers of neutrophils in the BALF (Figure 13C, 9.604x105 ± 1.625 
neutrophils in EC-SOD KO mice and 5.270x105 ± 0.635 neutrophils in wild-type mice) and 
higher MPO activity in the lungs (Figure 13D) of EC-SOD KO mice when compared to wild-
type mice 24 hours following E. coli inoculation.  EC-SOD KO mice also had significantly more 
protein in their BALF than wild-type mice 24 hours following infection (Figure 13E). These 
results are consistent with many prior studies, which have shown that EC-SOD expression in the 
lung inhibits inflammation in response to a wide variety of pulmonary injuries98, 99, 103, 144.   
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Figure 13: EC-SOD knockout mice have increased inflammation compared to wild-type mice. 
Hematoxylin and eosin staining of lung sections from wild-type and EC-SOD knockout (KO) mice sacrificed at 0 
and 24 hours after inoculation with E. coli shows increased acute inflammation in the EC-SOD KO compared to 
wild-type mice (A). There was more inflammation (total cells) in the bronchoalveolar lavage fluid (BALF) of EC-
SOD KO mice when compared to wild-type mice 24 hours after infection (B).  Differential counting demonstrates 
this inflammatory response was mainly due to an increase in neutrophils in the BALF (C).  Myeloperoxidase (MPO) 
activity in lung homogenates also showed that EC-SOD KO mice had significantly greater neutrophilic 
inflammation when compared to wild-type mice after E. coli inoculation (D). Protein in the BALF was measured to 
assess injury and the lungs of EC-SOD KO mice had significantly more protein in the alveolar lining fluid than 
wild-type mice after infection (E).  Data are means (±SEM) analyzed by two-way ANOVA with a Bonferroni post-
test.  *p<0.05 shows significant difference between groups, †p<0.05 shows interaction hence a significant difference 
between wild-type and EC-SOD KO (n=6/strain for each timepoint) 
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3.3.2 Mice lacking EC-SOD have a greater bacterial burden in the lung after pneumonia 
Left lung homogenates from wild-type or EC-SOD KO mice at 0, 6, and 24 hours after E. coli 
inoculation were plated onto LB agar to determine the bacterial burden in the lungs.  This burden 
is reported as the percentage of bacteria cleared from the lungs over time relative to the average 
initial burden at 0 h (± SEM).  Wild-type mice cleared more bacteria than EC-SOD KO mice at 
both 6 hours (71.55 ± 4.694 versus 51.31 ± 6.637, n=11/strain) and 24 hours (99.90 ± 0.025 
versus 99.80 ± 0.019, n=6/strain) following bacterial inoculation (Figure 14).  Even though EC-
SOD KO mice had greater inflammation compared to wild-type mice (Figure 13), the EC-SOD 
KO mice were found to have significantly more viable bacteria in the lungs when compared to 
wild-type mice (Figure 14).  Although the differences between EC-SOD KO and wild-type mice 
were statistically significant at both 6 and 24 hours following bacterial inoculation (p=0.0217 
and p=0.0095, respectively), the biological significance of this difference at 24 hours is unclear 
as the bacterial clearance of both strains at 24 hours is nearly 100%. 
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Figure 14: EC-SOD knockout mice have greater bacterial burdens than wild-type mice after E. coli 
inoculation. 
Left lung homogenates from wild-type (WT) and EC-SOD knockout (KO) mice following exposure to E. coli were 
plated onto Luria-Bertani agar to determine the bacterial burden in the lungs.  Percent of bacterial clearance for each 
strain was calculated as the average CFUs at 0 hours minus the CFUs remaining in the lungs at 6 and 24 hours 
divided by the average CFUs at 0 hours multiplied by 100.  *p<0.05, unpaired t-test (n=11/strain at 6 hours; 
n=6/strain at 24 hours) 
3.3.3 EC-SOD is present in human and murine phagocytic inflammatory cells 
Prior studies have noted that EC-SOD is expressed in inflammatory cells103, 144, 182; however, the 
subcellular location and function are unknown.  In the present study, electron microscopic 
immunolocalization of EC-SOD in human neutrophils and macrophages in human lung sections 
reveal that EC-SOD is located within membrane bound vesicles of these cells (Figure 15A-C).  
Similarly, western blotting of extracts from alveolar macrophages isolated from untreated wild-
type and EC-SOD KO mice reveal the expression of both proteolyzed and full-length EC-SOD in 
wild-type cells (Figure 15D).  In addition to protein expression in these cells, EC-SOD activity 
was detected in the cell lysate from alveolar, peritoneal, and bone marrow-derived macrophages 
using a Nitro Blue Tetrazolium SOD activity stain (Figure 16) as described in the methods 
(Section 3.2.8).  
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Figure 15: EC-SOD is present human and mouse phagocytic cells. 
Immunogold labeling demonstrates the presence of EC-SOD in membrane bound vesicles of a polymorphonuclear 
leukocyte (A) and an alveolar macrophage (B).  Black dots represent Protein-A gold (10 nm particles) bound to 
rabbit anti-human EC-SOD immunoglobulin.  Non-immune rabbit IgG was used as a control and resulted in the 
absence of labeling (C).  Western blot analysis of cell lysates from wild-type and EC-SOD knockout (KO) alveolar 
macrophages (D) revealed EC-SOD expression in wild-type, but not in EC-SOD KO alveolar macrophages. + = 
mouse EC-SOD positive control.  Scale bar = 0.5 μm 
 
 
Figure 16: EC-SOD is active in mouse macrophages. 
Cell lysate were collected from alveolar (AM), peritoneal (PM), and bone marrow-derived macrophages (BMM) and 
the EC-SOD activity was assayed using the Nitro Blue Tetrazolium Activity Gel. CuZn-SOD (21.2 µg) and EC-
SOD (2 µg) were used as positive controls.   
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3.3.4 Cellular EC-SOD affects macrophage antimicrobial defenses 
As phagocytic cell granules are known to contain a potent arsenal of compounds involved in 
antimicrobial defense, the novel finding that EC-SOD is stored inside and active in membrane 
bound vesicles in these cells suggests that EC-SOD may also play an important role in host 
defense against invading microbes. To study the role of EC-SOD in phagocytes, primary 
macrophages were isolated from the peritoneum or differentiated from bone marrow of wild-type 
and EC-SOD KO mice and the purity of the macrophage populations were determined by flow 
cytometry using Phycoerythrin-conjugated F4/80 (Table 2).  
Table 2. Purity of Primary Phagocyte Populations. 
3.3.4.1 Macrophages lacking EC-SOD produce more intracellular oxidants 
Electron paramagnetic resonance (EPR) spectroscopy was performed to determine the 
intracellular and extracellular oxidant production of wild-type and EC-SOD KO macrophages 
ten minutes after stimulation with PMA (Figure 17).  In the presence of the cell permeable spin 
probe CMH, EC-SOD KO macrophages stimulated with PMA produced approximately 2.5-fold 
more oxidants than PMA-stimulated WT cells (2.691 μM ± 0.5989 versus 1.049 μM ± 0.2240, 
N=2/strain).  Using the cell impermeable spin probe, PPH, there was no detectable extracellular 
oxidant production in PMA-stimulated wild-type or EC-SOD KO cells (Figure 17) suggesting 
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the oxidants produced by PMA stimulation were localized predominantly intracellularly.  No 
oxidant production was detected with un-stimulated wild-type and EC-SOD KO macrophages 
exposed to either CMH or PPH spin probes (Figure 17).   
 
Figure 17: Macrophages lacking EC-SOD have more intracellular ROS production. 
Peritoneal macrophages isolated from wild-type and EC-SOD knockout (KO) mice in Krebs HEPES buffer (pH 7.4) 
were exposed to 50 μM cell-permeable spin probe 1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine 
(CMH) or 50 μM non cell-permeable spin probe 1-hydroxy-4-phosphono-oxy-2,2,6,6-tetramethylpiperidine (PPH) 
and analyzed for the CM radical using a Bruker eScan Table-Top EPR spectrometer.  Oxidant generation was 
measured in these cells after stimulation with 15 μg/ml PMA.  1 μM CM radical standard was also shown as a point 
of reference.  Spectra represent 5 additive scans over 2 min at 37°C and are representative of three independent 
experiments.  Bar=10 Gauss 
 
The differences observed in oxidant production are not due to cell viability as cells that express 
and lack EC-SOD have similar viability when exposed to PMA (Figure 17).  These data provide 
strong evidence that EC-SOD within macrophages reduces oxidant levels produced during the 
respiratory burst in response to stimuli.   
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Figure 18: Cellular EC-SOD does not influence cell viability following PMA treatment. 
Bone marrow-derived macrophages isolated from wild-type and EC-SOD knockout (KO) mice were treated with 
various concentrations of phorbol 12-myristate 13-acetate (PMA) and the cell viability was measured using either a 
Promega CellTiter 96 AQueous Non-radioactive Cell Proliferation Assay Kit.     
3.3.4.2 Lack of EC-SOD in macrophages leads to altered pro-inflammatory cytokine 
expression  
In addition, bone marrow-derived macrophages from wild-type and EC-SOD KO mice were 
isolated, cultured, and exposed to 1 µg/ml LPS. Media was removed from the cells at various 
times after LPS treatment and the pro-inflammatory cytokine TNF-α levels were measured by 
ELISA.  EC-SOD KO macrophages released significantly more TNF-α 8 hours after treatment 
with endotoxin compared to wild-type macrophages with normal expression of EC-SOD (Figure 
19).  However, it was also observed that this trend was not the same at later time points and EC-
SOD KO cells were even seen to produce less TNF-α than wild-type cells 48 hours after 
endotoxin treatment.  Although perplexing, these results suggest that leukocyte-derived EC-SOD 
may alter pro-inflammatory cytokine production.  However, additional cytokine profiling, 
especially in the BALF of EC-SOD KO and wild-type mice following bacterial inoculation, is 
necessary before any conclusions can be drawn from this finding.     
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Figure 19: The presence of EC-SOD alters TNF-α secretion in response to LPS stimulation. 
Bone marrow-derived macrophages were isolated and cultured from wild-type (WT) and EC-SOD knockout (KO) 
mice.  Once differentiated, the cells were treated with lipopolysaccharide (LPS) and media was removed at various 
time points.  TNF-α levels in the media were measured using an ELISA. *p<0.05  
3.3.4.3 Cellular EC-SOD is necessary for efficient bacterial killing in vitro 
While potential beneficial effects of releasing EC-SOD from activated neutrophils and 
macrophages for the surrounding host tissue are apparent, it is less clear what the role of EC-
SOD will be on the actual anti-microbial function of these cells, however the in vivo data suggest 
that EC-SOD improved bacterial clearance (Figure 14).  In vitro studies were performed to 
assess bacterial clearance in wild-type and EC-SOD KO cells.  Bacterial killing assays revealed 
that macrophages lacking EC-SOD do not kill bacteria as efficiently as wild-type macrophages 
(Figure 20).  Specifically, macrophages containing EC-SOD killed a significantly greater 
percentage of bacteria than EC-SOD-lacking cells (51.48 ± 8.756 versus 6.471 ± 6.587, p= 
0.0143).  These in vitro findings are consistent with the in vivo studies that demonstrate 
decreased bacterial clearance in EC-SOD KO mice in a model of bacterial pneumonia (Figure 
14).  These findings, in conjunction with the EPR studies above (Figure 17), suggest that EC-
SOD might play an important role in macrophage-mediated bacterial clearance by regulating 
oxidants produced during the oxidative burst.  
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Figure 20: Macrophages lacking EC-SOD have decreased bacterial killing ability. 
Bone marrow-derived macrophages from wild-type (WT) and EC-SOD knockout (KO) mice were isolated and 
incubated for one hour with EGFP-expressing E. coli to assess the bacterial killing ability of these cells.  Following 
incubation, the bacteria remaining was determined by colony counting and the percentage of bacteria killed was 
calculated as the average CFUs of the bacteria alone minus the CFUs remaining after one hour incubation with cells 
divided by the average CFUs of the bacteria alone multiplied by 100.  n=3/strain, unpaired t-test; *p=0.0143 
3.3.4.4 Macrophages lacking EC-SOD have impaired phagocytic ability in vitro 
To further delineate the role EC-SOD plays in macrophage-mediated bacterial clearance, live 
cell imaging was performed to visualize the dynamic interactions between EGFP-expressing E. 
coli and phagocytes expressing or lacking EC-SOD over a one hour period. Phagocytosis was 
assessed by enumerating the number of cells that phagocytosed at least one bacteria as well as 
the number of bacteria phagocytosed per cell in 10-15 random fields.  These studies revealed that 
macrophages expressing EC-SOD (wild-type cells) are able to effectively phagocytose EGFP-
expressing E. coli, while macrophages lacking this antioxidant enzyme (EC-SOD KO cells) have 
impaired phagocytosis (Figure 21).  
 
  76 
 
Figure 21: Lack of cellular EC-SOD impairs bacterial phagocytosis. 
(A) Live cell imaging of bacterial phagocytosis was performed by incubating bone marrow-derived macrophages 
isolated from wild-type (WT) and EC-SOD knockout (KO) mice with EGFP-expressing E. coli (green).  Images (10 
min intervals, 40x magnification) show bacteria associating with and being phagocytosed by wild-type macrophages 
(arrows depict bacteria being internalized (phagocytosed) by the macrophages).  However, although bacteria 
associate with EC-SOD KO macrophages, they are not phagocytosed as is evident by observing that the bacteria 
remain on the cell surface of these macrophages over 1 hour after addition of bacteria (arrows point to bacteria 
associating with the macrophage, but they are never phagocytosed). Phagocytosis was quantified as the number of 
macrophages that phagocytosed bacteria (B, Fisher’s exact test) and the number of bacteria that were phagocytosed 
(phagocytic events) per cell (C, unpaired t-test).  n=total cells analyzed; *p<0.05 
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This difference in macrophage function is not due to reduced cell viability as there is no 
difference in viability observed between cells that expressed or lacked EC-SOD following 
treatment with LPS (Figure 22) or EGFP-expressing E. coli (visual assessment with trypan blue).  
This effect was also found to be specific for phagocytosis as endocytosis of fluorescent-
conjugated dextran over one hour was not affected by the absence of EC-SOD (Figure 23). These 
results suggest that macrophage expression of EC-SOD has an important function in promoting 
efficient bacterial phagocytosis. 
 
Figure 22: Cellular EC-SOD does not influence cell viability following exposure to LPS. 
Bone marrow-derived macrophages isolated from wild-type and EC-SOD KO mice were treated with various 
concentrations of lipopolysaccharide (LPS) and the cell viability was measured using either a Promega CellTiter 96 
AQueous Non-radioactive Cell Proliferation Assay Kit.     
 
 
Figure 23: Endocytosis is not altered by intracellular EC-SOD in phagocytes. 
Bone marrow-derived macrophages were cultured from wild-type and EC-SOD knockout (KO) mice and incubated 
with 5 µg/mL Alexa Fluor® 555 dextran for 1 hour.  No differences in endocytosis (A and B) were observed 
between cells that express or lack EC-SOD.  Results shown are from cells isolated and differentiated independently 
from four mice per strain. 
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3.4 DISCUSSION 
Production of ROS is essential for antimicrobial defense, but this response needs to be carefully 
regulated to minimize the amount of damage to the surrounding tissue.  The present study 
demonstrates that EC-SOD inhibits inflammation, while increasing bacterial clearance in a 
murine model of bacterial pneumonia.  In addition, these studies indicate that one mechanism in 
which EC-SOD contributes to bacterial clearance is by promoting bacterial phagocytosis and 
killing by macrophages.  These novel findings demonstrate that production of oxidants is not 
sufficient to eliminate an infection, but in fact the regulation of oxidant production by EC-SOD 
may be necessary for effective phagocytosis and killing of bacteria.   
Indeed, recent studies have highlighted the importance of oxidant production in the 
induction and regulation of innate immunity, especially in the context of CGD.  Patients with 
CGD are known to have defective phagocyte NADPH oxidase activity resulting in decreased 
O2•- generation, which strongly correlates with increased incidence of life-threatening infections 
and excessive inflammation.  Macrophages from these patients are known to have abnormal 
function as these cells release higher levels of anti-inflammatory cytokines and lower levels of 
pro-inflammatory cytokines in response to bacterial stimuli212.  Similarly, a study using a murine 
model of CGD further implicated oxidants as a critical regulator of the innate response as 
NADPH oxidase was shown to activate the anti-inflammatory transcription factor Nrf-2 and 
inhibit the pro-inflammatory transcription factor NF-κB thereby limiting inflammation213.  
Together, these findings show that oxidants produced via NADPH oxidase play a crucial role in 
regulating inflammation and host defense. 
Numerous studies have also directly shown that antioxidant activity is necessary to 
regulate macrophage function.  Specifically, EC-SOD has been shown to attenuate LPS-induced 
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inflammation in the lung by decreasing pro-inflammatory cytokine release from phagocytes197.  
Similarly, the antioxidant N-acetylcysteine has been shown to modulate the macrophage 
phagocytic response to endotoxin by decreasing the production of ROS and the release of the 
pro-inflammatory cytokine, TNF-α214, 215.  This effect was found to be potentially due to its 
ability to undergo cellular uptake and therefore influence the oxidant-induced intracellular signal 
transduction activity within the phagocyte215.  A more recent study found that hyperoxia reduces 
macrophage phagocytosis and that exogenous SOD treatment preserved actin cytoskeleton 
organization and phagocytosis of Pseudomonas aeruginosa216.  These findings suggest that 
decreased O2•- scavenging may directly contribute to the defective phagocytosis observed in 
these cells. The present work further supports these previous studies in finding that regulation of 
oxidant production is important in promoting macrophage function. While prior studies found 
that administration of antioxidants or oxidative stress altered macrophage phagocytosis, the 
current study demonstrates that endogenous expression of EC-SOD inside membrane bound 
vesicles in these cells directly regulates oxidant production during the respiratory burst and is 
necessary to promote effective phagocytosis and bacterial killing.  It is still unclear whether 
unregulated or elevated oxidant production directly affects the ability of phagocytes to recognize 
and/or ingest the microbes.  However, the live cell imaging studies suggest bacteria are 
associating with macrophages lacking EC-SOD, but are not being phagocytosed.  Further 
research will need to be conducted to fully understand how EC-SOD located inside phagocytic 
inflammatory cells modulates phagocytosis by controlling the oxidative environment in these 
cells.   
A recent study has shown that an antioxidant mimetic, MnTE-2-PyP, was able to 
significantly decrease the number of Mycobacterium abscessus growing inside infected 
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macrophage-like cells by promoting increased fusion of M. abscessus-containing phagosomes 
with lysosomes217.  Thus, promoting phagolysosome formation may be one mechanism in which 
EC-SOD stimulates bacterial clearance by macrophages. 
The present data describe a novel and important function for EC-SOD inside membrane 
bound vesicles of macrophages and neutrophils in the innate inflammatory defense against 
bacterial infection.  Western blot analysis of alveolar macrophage cell lysates from wild-type 
mice show the presence of both full-length and proteolyzed EC-SOD inside these phagocytes.  
While protease inhibitors were present during the isolation of proteins from these cells, 
macrophages contain high amounts of proteases.  Therefore, it is unknown whether the EC-SOD 
in macrophages is all full-length EC-SOD that underwent adventitious proteolysis during cell 
lysis or if the western blot analysis is a true reflection that macrophages contain a mixture of 
both proteolyzed and full-length EC-SOD. Regardless, the current findings suggest that EC-SOD 
present in phagocytic inflammatory cells is enzymatically active and plays a central role in 
promoting bacterial killing by modulating phagocytosis.  Although EC-SOD in phagocytic cells 
contributes to innate host defense against gram-negative bacterium, future investigations into the 
role of EC-SOD in other infection models will need to be conducted to determine whether its 
role is conserved for other bacterial infections as well.   
In summary, these studies describe a novel and important function for EC-SOD inside of 
macrophages and neutrophils in the innate inflammatory defense against bacterial infection 
(Figure 24). These studies suggest that EC-SOD present in phagocytic inflammatory cells plays a 
central role in bacterial clearance. It is interesting that all models of lung injury examined to date 
result in a marked accumulation of EC-SOD in the alveolar lining fluid. This accumulation of 
EC-SOD in response to pulmonary injury may play an important role in defense against bacterial 
  81 
infection (Figure 24). Thus, supplementation of EC-SOD may also be useful as an adjuvant to 
normal antibiotic therapy in the treatment of pneumonia and other bacterial infections. 
 
Figure 24: Proposed Role of EC-SOD within phagocytic cells. 
EC-SOD in wild-type phagocytes promotes bacterial phagocytosis. This leads to effective clearance of bacterial 
pathogens and decreased oxidative injury, which in turn promotes efficient resolution of inflammation and minimal 
tissue injury. The absence of EC-SOD in inflammatory cells (EC-SOD KO) impairs bacterial phagocytosis and thus 
causes prolonged infection and the recruitment of additional inflammatory cells. This additional inflammation 
accentuates production of reactive oxygen species and release of proteases resulting in increased tissue injury. Based 
on its role in regulating inflammation and phagocytosis and killing, treatment with exogenous EC-SOD would likely 
stimulate more effective bacterial clearance while inhibiting further inflammation and oxidative tissue injury. 
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4.0  FINAL DISCUSSION 
Endogenous antioxidant enzymes are normal cellular defenses that can protect against oxidant-
induced tissue injury.  EC-SOD is highly expressed in the lung and arteries and is bound to the 
ECM via its positively charged matrix-binding domain159-161, 181.  Although it was well 
established that EC-SOD is lost from the lung interstitium and accumulates in the alveolar lining 
fluid in response to a variety of pulmonary insults and infections, the significance of this 
accumulation was unclear.  In addition to its localization on matrices and in extracellular fluids, 
EC-SOD is also present intracellularly in neutrophils and macrophages103, 144, 182.  However, prior 
to the studies described above, the localization and the functional role of EC-SOD in leukocytes 
were unknown.   
Two different pulmonary disease models were employed to study the role of leukocyte-
derived EC-SOD: the asbestos-induced ILD model and the bacterial pneumonia model.  The ILD 
model shows effects primarily in the interstitium that are characterized by interstitial 
inflammation and fibrosis with some additional inflammation in the airspaces.  In contrast, the 
bacterial pneumonia model demonstrates inflammation primarily in the airspaces in the absence 
of interstitial involvement.  Although these model systems produce pathologically different 
injuries in the lung, there is commonality in that the biological function of EC-SOD in each 
injury largely depends upon its location in the lung.   
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4.1 DISCUSSION OF EC-SOD IN THE LUNG AND AIRSPACES 
First, the localization of EC-SOD in the lung is crucial for protecting the interstitium from 
oxidative injury.  In the normal lung, EC-SOD is bound to the ECM via its positively charged 
matrix-binding domain160.  It is through this physical interaction that EC-SOD has been shown to 
prevent the oxidative fragmentation of numerous ECM components170, 171, 198, 199.  The protection 
of the tissue matrix by EC-SOD has been shown to be one mechanism by which EC-SOD 
prevents inflammation and fibrosis following interstitial lung injury144, 171, 198.  Overall, loss of 
EC-SOD from the lung is detrimental to the host tissue.  A recent study using a Cre-Lox system 
to induce an acute loss of EC-SOD resulted in 85% mortality secondary to spontaneous 
development of acute pulmonary inflammation with a histologic appearance similar to ARDS200.  
This study shows that EC-SOD in the lung plays a vital role in continuously protecting it from 
injury even in ambient air. 
It is interesting that all models of lung injury (interstitial lung injury and infection) 
examined to date result in a marked accumulation of EC-SOD in the alveolar lining fluid.  It was 
originally thought that leukocytes could transport and release EC-SOD into the alveolar lining 
fluid in response to interstitial lung injury.  However, the present findings confirm that airspace 
EC-SOD detected after interstitial lung injury is from the lung parenchyma and not an 
extrapulmonary source.  As all the EC-SOD that accumulates in the BALF is from the 
interstitium, therapies to minimize the loss of EC-SOD from the lung may prove to be beneficial 
for the treatment of ILDs.  
Although this depletion of full-length EC-SOD from the lung parenchyma is detrimental 
in this disease, proteolyzed EC-SOD is known to be enzymatically active165.  Therefore, the 
retention of EC-SOD in the airspaces may be an adaptive and protective mechanism to limit 
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inflammation and injury to airway epithelial cells.  This is evident by the fact that both 
inflammation and fibrosis are increased when EC-SOD is completely absent from the lung.  
Specifically, EC-SOD KO mice are reported to have increased inflammation and fibrosis when 
compared to wild-type mice in numerous models of interstitial lung injury98, 144.  In addition, EC-
SOD has been found to have a novel and important role in the regulation of innate immune 
defense by promoting the phagocytosis and killing of gram-negative bacterium by macrophages.  
In light of this current work, it is possible that airspace EC-SOD could increase macrophage 
phagocytosis and killing to help prevent the occurrence of bacterial infections (Further discussed 
in Section 4.3.3). 
Although leukocytes are not the source of airspace EC-SOD following interstitial lung 
injury, the present findings in conjunction with previous work103 strongly suggest that EC-SOD 
is released from inflammatory cells into the airspace following bacterial pneumonia.  Indeed, 
many studies have noted that EC-SOD is present in leukocytes103, 144, 182.  The present work 
furthers this current knowledge by showing that EC-SOD is contained in intracellular vesicles 
(Figure 15).  This work also demonstrates that both full-length and proteolyzed EC-SOD are 
detected inside of murine alveolar macrophages.  Therefore, this novel intracellular localization 
of EC-SOD may infer that EC-SOD could be released upon cell activation into the airspace.  
Interestingly, a mixture of full-length and proteolyzed EC-SOD was detected in the BALF of 
wild-type mice 6 hours after bacterial inoculation possibly suggesting that EC-SOD is released 
from these cells as the full-length protein.  By 24 hours following bacterial inoculation, the 
majority of the EC-SOD found in the BALF was proteolyzed EC-SOD potentially due to 
proteolytic cleavage of this antioxidant enzyme that occurred in the extracellular fluids.   
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Once in the airspace, full-length EC-SOD has the capacity to interact directly with the 
bacterium via its positively charged matrix-binding domain as the surface coating (LPS and 
anionic lipids) and bacterial membrane (acidic phospholipids) of gram-negative bacterium make 
it negatively charged.  Therefore, full-length EC-SOD could coat the bacterium and possibly 
serve as an “antioxidant-opsonizing agent” to enhance bacterial phagocytosis.  In addition, full-
length EC-SOD is known to be endocytosed into endothelial cells through clathrin-mediated 
pathway218.  However, in a recent study, Pasupuleti and colleagues generated a peptide that 
corresponded to that C-terminal region of EC-SOD (RQAREHSERKKRRRESECKAA) and 
observed that this peptide was able to induce membrane leakage of negatively charged liposomes 
(such as gram-negative bacterium)219.  Their results suggest the C-terminal domain of EC-SOD 
can directly kill the bacteria, however, these effects were abrogated at physiological salt 
conditions as well as in plasma.  The current study challenges these findings as clear differences 
in phagocytic ability were observed between EC-SOD expressing cells and EC-SOD KO cells.  
Furthermore, incubation of E. coli with full-length EC-SOD did not result in decreased bacteria 
viability in our hands.  Unlike in an in vitro system, it is also likely that the C-terminal domain is 
rapidly cleared or further degraded when it is proteolytically cleaved from EC-SOD in vivo. 
Overall, the presence of EC-SOD is clearly essential for its function; however whether or not 
EC-SOD confers matrix affinity might also influence its role in innate immunity.   
4.2 DISCUSSION OF CELLULAR EC-SOD 
As its location is essential for protecting the lung parenchyma, the intracellular location of EC-
SOD in macrophages is now shown to be necessary for efficient phagocytosis.  This work is the 
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first to report that EC-SOD plays a novel and important role in the regulation of innate immune 
defense by promoting the phagocytosis and killing of gram-negative bacterium by macrophages.  
In the lung, macrophages are the first inflammatory cells to encounter microbes and particulates 
that enter alveolar spaces and are continually eliminating these airborne substances without 
inducing inflammation.  However, if they are unable to clear the microbes, macrophages recruit 
neutrophils into the lung to help eradicate the infection.  Macrophages therefore are exposed to 
large quantities of ROS and RNS produced endogenously or by activated neutrophils, which may 
alter microbial recognition and phagocytosis via pattern recognition receptors.  Indeed, a study 
by Bozeman and colleagues showed that exogenous and endogenously-produced H2O2 by 
neutrophils inhibited ligand binding to the mannose receptors on rat macrophages and decreased 
the number of macrophage mannose receptors on the cell surface220.  Conversely, studies have 
also shown that oxidants can enhance phagocytosis.  For instance, both exogenous and 
endogenously-produced H2O2 enhanced the phagocytic capacity of neutrophils221.  In this same 
study, Pricop and others also show that human monocytes incubated in the presence of 
stimulated neutrophils showed increased Fcγ receptor signaling and amplified phagocytosis221.  
In this case, the reactive oxygen species generated in an inflammatory environment act in an 
autocrine and paracrine manner to rapidly increase Fcγ receptor-mediated phagocytosis.  In the 
context of the current findings, leukocyte-derived EC-SOD may change the composition of 
oxidants during the respiratory burst creating a favorable environment for phagocytosis of gram-
negative bacterium.  EC-SOD in leukocytes may lower steady state levels of O2•- as EC-SOD KO 
cells produced more oxidants following PMA stimulation.  However, EC-SOD in leukocytes 
may lower, raise, or not alter H2O2 levels depending on the redox state of the environment.  
Therefore, elucidating the oxidant composition of the respiratory burst and determining which 
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oxidative species inhibit phagocytosis in macrophages lacking EC-SOD may assist in 
determining the regulatory role of EC-SOD in phagocytosis. 
In addition to affecting microbial recognition, ROS are capable of modulating 
mechanisms by activating transcription factors, increasing the levels of cytokines, chemokines, 
and other soluble pro-inflammatory factors, and altering the expression of cell surface adhesion 
molecules.  Specifically, activation of the redox-sensitive transcription factor NF-κB has been 
shown to induce the expression of pro-inflammatory cytokines, chemokines, and adhesion genes.  
Under normal conditions, NF-κB is maintained in the cytosol in a complex with its inhibitor, 
IκB.  Upon cell activation by cytokines or endotoxin, IκB is phosphorylated on specific serines, 
inducing a release from NF-κB, which can go to the nucleus and activate transcription of pro-
inflammatory mediators.  All protein-tyrosine phosphatases have a reactive cysteine residue in 
their active site, which must be reduced for catalytic activity.  Therefore, ROS can inhibit 
activity of these phosphatases through reversible oxidation of their catalytic site, while 
antioxidants would protect these important regulators of intracellular signaling222, 223.  Because 
ROS and RNS are shown to mediate cell-signaling events in inflammation, EC-SOD in 
leukocytes could play an important role in the inflammatory response by limiting the availability 
of these reactive species to participate in these reactions.   
In agreement with the present work, other studies have noted the importance of 
intracellular antioxidants in modulating these inflammatory cell responses.  Indeed, a study by 
Bulger and others examined the effect of intracellular and extracellular antioxidants on the 
alveolar macrophage response to endotoxin and found that only intracellular antioxidants were 
able to mediate the macrophage response to inflammatory stimuli215.  Overall, intracellular signal 
transduction activity of ROS is crucial to macrophage pro-inflammatory activation and 
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intracellular EC-SOD would be vital for regulating these responses and this would potentially be 
one mechanism by which leukocyte-derived EC-SOD limits inflammation following bacterial 
infection.   
Other studies have noted the importance of EC-SOD in modulating inflammation.  For 
instance, LPS-induced lung inflammation was found to be exaggerated in EC-SOD KO mice 
while diminished in mice overexpressing the EC-SOD protein in their lungs197.  In this study, 
lack of EC-SOD expression was correlated with increased pro-inflammatory cytokine release 
both in vivo and in vitro as well as increased expression of cell adhesion molecules necessary for 
neutrophil extravasation197.  This LPS-mediated release of TNF-α and MIP-2 was also attenuated 
by EC-SOD treatment.  As EC-SOD has been shown to regulate the release of cytokines, 
cytokines have also been shown to regulate EC-SOD.  The pro-inflammatory cytokines, such as 
IL-1 and interferon-γ, have been shown to increase EC-SOD expression in both fibroblasts and 
type II epithelial cells224, 225.  The presence of pro-inflammatory cytokines is associated with 
increased NF-κB activation and this increased in NF-κB activation has been shown to regulate 
EC-SOD transcription175, 225.  Together, these studies suggest that the location of EC-SOD inside 
leukocytes would be a prime location for its role in the augmentation of oxidant-mediated 
induction of inflammation.   
Although the underlying mechanism is still unknown, it is clear that leukocyte-derived 
EC-SOD promotes phagocytosis and limits inflammation.  One potential mechanism in which 
EC-SOD functions in this capacity as suggested by the literature is by preventing oxidant-
mediated damage/inactivation of cell surface receptors and excessive cell activation.  Overall, the 
presence of EC-SOD inside phagocytic cells allows for efficient phagocytosis while the absence 
of this protein leads to impaired or frustrated phagocytosis and ultimately less bacterial 
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clearance.  Impaired phagocytosis can augment inflammation and tissue injury due to constant 
stimulation of inflammatory and epithelial cells by the unresolved bacterial infection.  This will 
lead to increased release of pro-inflammatory cytokines and chemokines that further induce 
inflammation.  Indeed, studies have found that decreased phagocytic activity of neutrophils 
contributes to the development of sepsis in response to bacterial infections226.  In this regard, the 
localization of EC-SOD in phagocytes is vital to promote innate immune responses and to limit 
inflammation and subsequent injury in the lung.   
4.3 ADDITIONAL CONSIDERATIONS & FUTURE DIRECTIONS 
This work is the first to describe that EC-SOD inside leukocytes promotes bacterial phagocytosis 
and killing of gram-negative bacterium.  With this novel finding comes a plethora of new 
avenues of research to better understand how this antioxidant regulates the function of immune 
cells.  The goal of this section is to present some additional considerations for the current work 
as well as highlight a few future experiments that will serve as tools to uncover the novel 
mechanism behind the regulation of leukocyte-derived EC-SOD in innate immunity.   
4.3.1 Determine if leukocytes are source of airspace EC-SOD following bacterial 
inoculation  
The present findings in conjunction with previous work103 strongly suggest that EC-SOD is 
released from inflammatory cells into the airspace in response to bacterial inoculation and this 
leukocyte-derived EC-SOD limits inflammation by promoting bacterial phagocytosis and killing.  
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However, it is possible that the up-regulation of EC-SOD by type II alveolar epithelial cells 
could also account for the accumulation of EC-SOD in the alveolar lining fluid without a loss 
from the parenchyma as TNF-α and interferon-γ are potent inducers of EC-SOD expression in 
these cells225. 
To positively conclude leukocytes deliver and release EC-SOD to sites of active 
inflammation following bacterial inoculation, BMC mice will need to be generated as discussed 
in Chapter 2.  If leukocytes are the sole source of EC-SOD in the airspace following bacterial 
pneumonia, EC-SOD will be detected in the BALF of KO/WT mice, which express EC-SOD 
only in their inflammatory cells.  In addition, EC-SOD will not be present in the BALF of 
WT/KO mice that only have pulmonary EC-SOD expression.  It is possible that both cell types 
could contribute to the EC-SOD present in the airspace.  Therefore, the levels of EC-SOD in the 
BALF of WT/WT (total EC-SOD released), WT/KO (type II alveolar epithelial cells), and 
KO/WT (leukocytes) mice can be compared to deduce the relative contribution of each cell type.  
Regardless, the present in vitro experiments have shown that intracellular EC-SOD is important 
for macrophage function and thus leukocyte-derived EC-SOD is still essential for host defense 
against gram-negative bacterium. 
The current findings also strongly suggest that leukocyte-derived EC-SOD reduces 
inflammation while promoting bacterial clearance by enhancing macrophage phagocytosis and 
killing.  Therefore, it is hypothesized that these BMC studies will also show that EC-SOD 
expression in phagocytic cells plays an important role in augmenting bacterial clearance and 
limiting inflammation in bacterial pneumonia. This will be evident if there is decreased 
inflammation and increased bacterial clearance (decreased bacterial burden in the lungs) in BMC 
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mice that have EC-SOD in the inflammatory cells but no pulmonary expression of EC-SOD 
(KO/WT) when compared to BMC mice that completely lack EC-SOD expression (KO/KO). 
4.3.2 Determine if EC-SOD promotes phagocytosis of all microbes 
The current findings presented in this dissertation show that macrophages expressing EC-SOD 
(wild-type cells) display normal phagocytic and killing activity of the gram-negative bacterium 
E. coli.  While on the other hand, macrophages lacking this antioxidant enzyme cannot 
efficiently phagocytose and kill this bacterium.  These in vitro findings are also correlated in vivo 
as EC-SOD KO mice had greater inflammation and bacterial burden in their lungs than wild-type 
mice after bacterial inoculation.  However, it is possible that EC-SOD is only necessary for the 
phagocytosis and killing of gram-negative bacterium.  To test if leukocyte-derived EC-SOD 
promotes macrophage function in general, the ability for EC-SOD-expressing cells and cells that 
lack EC-SOD to phagocytosis different microorganisms, such as gram-positive bacterium, as 
well as opsonized particles will need to be assessed.  Identifying whether or not this response is 
non-specific or exclusive for gram-negative bacterium will not only allow for a deeper 
understanding of the role of EC-SOD in host defense, but more importantly may reveal essential 
cell-surface receptors for regulating this response for future studies.   
Despite whether or not EC-SOD promotes the phagocytosis and killing of all 
microorganisms equally, the current findings would suggest that all types of macrophages would 
respond similarly to gram-negative bacterium regardless of the host tissue as both bone marrow-
derived and peritoneal macrophages were used in the in vitro studies presented in this 
dissertation.  Therefore, these results may not only be relevant to pulmonary infections, but 
applicable for limiting inflammation and infection in other organs. 
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4.3.3 Dynamics of EC-SOD and macrophages 
The present work is the first to report that EC-SOD is located in membrane bound vesicles inside 
macrophages and neutrophils.  However, the exact subcellular location is still ambiguous.  
Without further classification, it is difficult to determine if EC-SOD is present in endocytic or 
exocytic vesicles.  The in vivo bone marrow chimera studies described above (Section 2.2.1) 
could help make this distinction, but in vitro studies could also be conducted to determine if 
activated phagocytes release EC-SOD by measuring the levels of EC-SOD release into the media 
following cell stimulation.   
As a study has observed that full-length EC-SOD is able to be endocytosed218, the 
possibility still exists that phagocytes also have the capacity to uptake EC-SOD regardless of the 
presence of its matrix-binding domain.  Fluorescently labeling EC-SOD and observing its 
behavior in the presence of stimulated and unstimulated cells using in vitro microscopy 
techniques would likely be valuable for testing this hypothesis.  As macrophages and neutrophils 
are phagocytes, it is possible that they can uptake EC-SOD through normal processes and 
therefore store this protein in endocytic vesicles.   
Preliminary experiments show that exogenous EC-SOD and CuZn-SOD can restore 
bacterial phagocytosis thereby promoting bacterial clearance (Figure 25).  This suggests the 
enzymatic activity is what is important as CuZn-SOD and EC-SOD could restore phagocytosis.  
It is important to note, however, that EC-SOD appears to be a more potent inducer of 
phagocytosis as 10 fold less EC-SOD produces a more complete restoration when compared to 
CuZn-SOD.  Overall, the movement and location of EC-SOD inside and outside the cell in 
response to bacterial stimuli will help better determine the dynamic role EC-SOD may play in 
regulating macrophage function and ultimately innate immunity.   Although the underlying 
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mechanism is unclear, the location of EC-SOD in the alveolar lining fluid following bacterial 
inoculation is likely vital for its function in innate immune defense. 
 
Figure 25: Exogenous SOD treatment promotes bacterial phagocytosis in EC-SOD KO macrophages. 
Bone marrow-derived macrophages from wild-type and EC-SOD KO mice (stained with CellTracker Orange 
CMRA) were incubated with EGFP-expressing E. coli (green) for 2 hrs and in the presence of CuZn-SOD and EC-
SOD. Phagocytosed bacteria were visualized by confocal microscopy. Wild-type macrophages phagocytosed the 
bacteria (A), while EC-SOD KO macrophages showed no evidence of bacterial phagocytosis (B). However, 
phagocytosis could be restored in EC-SOD KO macrophages by addition of 10 units of EC-SOD (C) or 100 units of 
CuZn-SOD (D). All images are maximum z projections (composite of 30 z sections, 2 µm apart).   
4.3.4 Investigate oxidant-mediated inhibition of phagocytosis 
The present data indicates that macrophages from EC-SOD KO mice do not phagocytose 
bacteria, which suggests that scavenging O2•- is necessary to promote bacterial phagocytosis and 
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killing.  While lack of EC-SOD will increase the steady state concentration of O2•-, it can also 
alter many other ROS downstream of O2•- in the reduction of oxygen to water.  Thus, it is unclear 
which oxidative species are responsible for regulating EC-SOD dependent phagocytosis.   
Since SODs are O2•- scavengers and preliminary results show administration of 
exogenous EC-SOD or CuZn-SOD restores bacterial phagocytosis in the EC-SOD KO 
macrophages (Figure 25), it is hypothesized that oxidants that are scavenged or prevented from 
forming by EC-SOD may interfere with normal phagocytosis and killing.  If our hypothesis is 
correct and O2•- and •OH are responsible for the deficient bacterial phagocytosis seen in EC-SOD 
KO cells, catalase (scavenging H2O2) should have no or some effect on restoration of 
phagocytosis in EC-SOD KO cells. However, we may find equivalent restoration of 
phagocytosis with catalase.  Although we do not expect this result, this would suggest that either 
H2O2 itself is playing a major role in the altered phagocytosis seen in EC-SOD KO cells or that 
•OH produced from iron catalyzed Haber-Weiss reactions227 is the predominant mechanism by 
which the loss of EC-SOD inhibits phagocytosis. If there is only a partial recovery of 
phagocytosis with catalase treatment, it may suggest that ONOO- generation of •OH is also 
contributing to this effect.  As •OH can be produced by the breakdown of ONOO-, one would 
expect that inhibition of NOS with Nω-nitro-L-arginine might partially restore phagocytosis in 
EC-SOD KO cells.  However, this would be in contrast to a prior study that showed inhibition of 
NOS inhibits bacterial phagocytosis228.  This study suggests that NO• itself is vital for 
phagocytosis and may indicate that all of EC-SOD’s effects are due to its abilities to inhibit O2•--
dependent inactivation of NO•229.  If this is correct, we expect that EC-SOD treatment will 
restore phagocytosis while no other scavengers will.   
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4.3.5 Determine the role of EC-SOD in neutrophils 
In addition to macrophages, EC-SOD is also known to be expressed in human and murine 
neutrophils.  The current findings show that even though EC-SOD KO mice initially had more 
bacterial burden than wild-type mice at 6 hours, these mice were able to begin to clear bacteria 
by 24 hours (Figure 14).  This is likely due to the fact that there is more neutrophilic 
inflammation and these cells produce large amounts of oxidants and other bactericidal substances 
that kill the bacteria, but in a way that may be harmful to the lung.  Unfortunately, the oxidative 
stress in the lungs of these mice is still unknown, as this was not investigated in the current work.  
Furthermore, the effect of EC-SOD on neutrophil function (i.e. phagocytosis and killing ability) 
is still uncertain.  Therefore, assessing the oxidative injury in the lung as well as examining the 
function of neutrophils in vitro could better indicate the role of neutrophil-derived EC-SOD in 
bacterial pneumonia.   
It is important to note that studies were attempted to isolate neutrophils from wild-type 
and EC-SOD KO mice and to investigate the role of EC-SOD in neutrophils.  However, 
preparation of mouse neutrophils from bone marrow using a three-layer Percoll gradient as 
described by Boxio and others was limited due to cell viability230.  A second method using 
intraperitoneal injection of casein to elicit neutrophils to the peritoneum231 was limited due to 
low purity as approximately 50% neutrophils and 50% macrophages were obtained from this 
isolation method.  Recently, a long-term bone-marrow culture system for neutrophils was 
described and was reported to be able to overcome the purity and short life-span issues of other 
methods232.  Therefore, this new method may be useful for future investigations involving 
neutrophils.  As pneumonias are characterized by a large influx of neutrophils, it is important to 
pursue studies to determine the role of neutrophil-derived EC-SOD in host defense.  
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4.3.6 Summary 
The current work is the framework for future investigations to better understand how EC-SOD 
regulates macrophage phagocytosis and killing.  Based on the current findings and preliminary 
results shown in this dissertation, macrophage phagocytosis and activation is likely altered by the 
oxidative environment.  Therefore, the exact localization of EC-SOD in a quiescent cell and its 
movement following cell activation will likely further reveal its role in macrophage immune 
function.   
4.4 CLINICAL IMPLICATIONS 
Acute lower respiratory infections are the leading cause of premature death with a greater disease 
burden than heart attacks, cancer, and HIV/AIDS12, 13.  In addition, pneumonia is a prevalent 
disease that can lead to complications such as sepsis and acute respiratory distress syndrome and 
can also complicate many other diseases, such as chronic obstructive pulmonary disease, ILDs, 
cystic fibrosis, and HIV/AIDS.  Despite advances in antimicrobial therapy, rates of pneumonia 
mortality have not decreased in the past 50 years12, 74.  Therefore, improvements in therapy for 
pneumonia especially for those patients at higher risk of this disease have the potential to have a 
large clinical impact.   
The novel finding that EC-SOD in leukocytes promotes bacterial phagocytosis and 
killing and limits inflammation supports the research and use of antioxidants for treatment of 
bacterial pneumonias.  While antibiotic therapies have been a great resource, treatment with EC-
SOD in conjunction with traditional antibiotics would likely result in more efficient bacterial 
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clearance and less oxidative damage to the host tissue.  Furthermore, treatment with EC-SOD 
may be valuable for eliminating antibiotic-resistance strains.  As bacterial infections are not 
limited to the lung, these findings are likely translatable to other bacterial infections as well. 
IPF is a relentlessly progressive and fatal pulmonary disorder with unknown etiology.  
Like other ILDs, there are no effective treatments for IPF.  The clinical course of IPF patients is 
generally marked by slow decline in pulmonary function over time, but a large number of 
patients have been recognized as having an acute, and often fatal, exacerbations characterized by 
a large influx of inflammatory cells into the BALF and lungs.   Pirfenidone, a drug that is known 
to act as an anti-inflammatory, anti-fibrotic, and antioxidant, was shown to decrease the 
prevalence of acute exacerbations in IPF patients233.  Although it was speculated that multiple 
biological functions of this drug may protect the fibrotic lung against the superimposed diffuse 
lung damage associated with acute exacerbations, significant adverse side effects were reported 
limiting its usefulness as a realistic prophylactic treatment option233.  Based on the presented 
work, EC-SOD is known to function in all three of the same biological capacities.  Therefore, 
although antioxidant therapies have been shown to be unsuccessful at preventing the progression 
of ILDs, it is likely antioxidant therapy could still represent a realistic therapeutic option in order 
to lower the prevalence of these exacerbations and increase survival of patients with IPF and 
other ILDs.   
Aside from all this, it is essential to better understand the molecular mechanisms that 
explain how EC-SOD regulates bacterial phagocytosis and killing and to determine if this effect 
is general for all types of infections or specific to gram-negative bacterium.  It is hoped that the 
research described in this dissertation will serve as a foundation for future research and will 
inspire diverse studies to better understanding the mechanism of how EC-SOD in leukocytes 
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attenuates infection.   Overall, it is the hope that the findings presented in this dissertation will 
serve as the foundation for the development of new innovative translational applications for EC-
SOD or other antioxidants in the treatment of bacterial pneumonia, non-pulmonary bacterial 
infections, and perhaps the prophylactic treatment for individuals at high risk of developing 
pneumonia and acute exacerbations.   
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